DE3413608A1
(de)
*
|
1984-04-11 |
1985-10-24 |
Hoechst Ag, 6230 Frankfurt |
Implantierbare zubereitungen von regulatorischen peptiden mit gesteuerter freisetzung und verfahren zu ihrer herstellung
|
IL79134A
(en)
*
|
1985-07-29 |
1991-06-10 |
American Cyanamid Co |
Continuous release peptide implants for parenteral administration
|
US5137874A
(en)
*
|
1985-07-29 |
1992-08-11 |
American Cyanamid Co. |
Partially coated C10 -C20 fatty acid salts of peptides having molecular weights up to about 5,000
|
US4761289A
(en)
*
|
1986-10-10 |
1988-08-02 |
International Minerals & Chemical Corp. |
Sustained release implant and method for preparing same
|
ATE151638T1
(de)
|
1987-02-20 |
1997-05-15 |
Genentech Inc |
Verfahren und zubereitungen für die verwendung von hiv-env-polypeptiden und antikörpern
|
DE3712095A1
(de)
*
|
1987-04-10 |
1988-10-20 |
Lentia Gmbh |
Bindemittelfreies granulat mit verzoegerter wirkstoffabgabe
|
DE3811231A1
(de)
*
|
1988-04-02 |
1989-10-12 |
Beiersdorf Ag |
Chirurgische implantate
|
DE59003337D1
(de)
*
|
1989-10-16 |
1993-12-09 |
Danubia Petrochem Polymere |
Pressling mit retardierter Wirkstofffreisetzung.
|
US5470582A
(en)
*
|
1992-02-07 |
1995-11-28 |
Syntex (U.S.A.) Inc. |
Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles
|
JP2651320B2
(ja)
*
|
1992-07-16 |
1997-09-10 |
田辺製薬株式会社 |
徐放性マイクロスフェア製剤の製造方法
|
US5877016A
(en)
|
1994-03-18 |
1999-03-02 |
Genentech, Inc. |
Human trk receptors and neurotrophic factor inhibitors
|
US5708142A
(en)
|
1994-05-27 |
1998-01-13 |
Genentech, Inc. |
Tumor necrosis factor receptor-associated factors
|
DE4423131A1
(de)
*
|
1994-07-01 |
1996-01-04 |
Bayer Ag |
Neue hIL-4-Mutantenproteine als Antagonisten oder partielle Agonisten des humanen Interleukin 4
|
US6093697A
(en)
*
|
1994-11-07 |
2000-07-25 |
The University Of Virginia Patent Foundation |
Synthetic insulin mimetic substances
|
US5599535A
(en)
*
|
1995-06-07 |
1997-02-04 |
Regents Of The University Of California |
Methods for the cyto-protection of the trabecular meshwork
|
US5674888A
(en)
*
|
1995-06-07 |
1997-10-07 |
University Of California |
Method for the treatment of a trabecular meshwork whose cells are subject to inhibition of cell division
|
US7005505B1
(en)
|
1995-08-25 |
2006-02-28 |
Genentech, Inc. |
Variants of vascular endothelial cell growth factor
|
US6020473A
(en)
*
|
1995-08-25 |
2000-02-01 |
Genentech, Inc. |
Nucleic acids encoding variants of vascular endothelial cell growth factor
|
US7888466B2
(en)
|
1996-01-11 |
2011-02-15 |
Human Genome Sciences, Inc. |
Human G-protein chemokine receptor HSATU68
|
US5985830A
(en)
*
|
1996-09-16 |
1999-11-16 |
Dalhousie University |
Use of IGF-I for the treatment of kidney disorders
|
EP2230307A1
(en)
|
1996-10-25 |
2010-09-22 |
Human Genome Sciences, Inc. |
Neutrokine alpha
|
US7390891B1
(en)
|
1996-11-15 |
2008-06-24 |
Amgen Inc. |
Polynucleotides encoding a telomerase component TP2
|
JP2002512521A
(ja)
|
1997-05-30 |
2002-04-23 |
ヒューマン ジノーム サイエンシーズ,インコーポレイテッド |
32個のヒト分泌タンパク質
|
US6342220B1
(en)
|
1997-08-25 |
2002-01-29 |
Genentech, Inc. |
Agonist antibodies
|
EP1015488B1
(en)
|
1997-09-17 |
2009-09-09 |
Human Genome Sciences, Inc. |
Interleukin-17 receptor-like protein
|
US5906979A
(en)
*
|
1998-01-27 |
1999-05-25 |
Insmed Pharmaceuticals, Inc. |
Compositions and methods for treating metabolic diseases characterized by hyperandrogenism and/or anovulation and/or infertility
|
EP2050762A3
(en)
|
1998-03-10 |
2009-07-08 |
Genentech, Inc. |
Human cornichon-like protein and nucleic acids encoding it
|
ATE405651T1
(de)
|
1998-03-17 |
2008-09-15 |
Genentech Inc |
Zu vegf und bmp1 homologe polypeptide
|
AU3072799A
(en)
|
1998-03-19 |
1999-10-11 |
Human Genome Sciences, Inc. |
Cytokine receptor common gamma chain like
|
US5973119A
(en)
*
|
1998-06-05 |
1999-10-26 |
Amgen Inc. |
Cyclin E genes and proteins
|
US6344541B1
(en)
|
1998-09-25 |
2002-02-05 |
Amgen Inc. |
DKR polypeptides
|
AUPP785098A0
(en)
|
1998-12-21 |
1999-01-21 |
Victor Chang Cardiac Research Institute, The |
Treatment of heart disease
|
US6303749B1
(en)
|
1999-01-29 |
2001-10-16 |
Amgen Inc. |
Agouti and agouti-related peptide analogs
|
US8624010B1
(en)
|
1999-02-03 |
2014-01-07 |
Steven K. Yoshinaga |
Nucleic acids encoding B7RP1
|
US7435796B1
(en)
|
1999-02-03 |
2008-10-14 |
Amgen Inc. |
Antibodies which bind B7RP1
|
HUP0105337A3
(en)
|
1999-02-03 |
2011-01-28 |
Amgen Inc |
Polypeptides involved in immune response
|
US7708993B2
(en)
|
1999-02-03 |
2010-05-04 |
Amgen Inc. |
Polypeptides involved in immune response
|
EP1161451A4
(en)
|
1999-02-26 |
2006-05-17 |
Human Genome Sciences Inc |
HUMAN ALPHA ENDOKIN AND METHOD FOR ITS USE
|
AU3770800A
(en)
|
1999-03-26 |
2000-10-16 |
Amgen, Inc. |
Beta secretase genes and polypeptides
|
US6635249B1
(en)
|
1999-04-23 |
2003-10-21 |
Cenes Pharmaceuticals, Inc. |
Methods for treating congestive heart failure
|
ES2392392T3
(es)
|
1999-06-28 |
2012-12-10 |
Genentech, Inc. |
Métodos para producir ligando Apo-2 utilizando iones metálicos divalentes
|
US7408047B1
(en)
|
1999-09-07 |
2008-08-05 |
Amgen Inc. |
Fibroblast growth factor-like polypeptides
|
US7459540B1
(en)
|
1999-09-07 |
2008-12-02 |
Amgen Inc. |
Fibroblast growth factor-like polypeptides
|
US7514239B2
(en)
|
2000-03-28 |
2009-04-07 |
Amgen Inc. |
Nucleic acid molecules encoding beta-like glycoprotein hormone polypeptides and heterodimers thereof
|
WO2001079480A1
(en)
|
2000-04-12 |
2001-10-25 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
CA2413160A1
(en)
|
2000-06-15 |
2001-12-20 |
Human Genome Sciences, Inc. |
Human tumor necrosis factor delta and epsilon
|
EP2042597B1
(en)
|
2000-06-23 |
2014-05-07 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
|
EP2168980A1
(en)
|
2000-06-23 |
2010-03-31 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of disorders involving angiogensis
|
JP2004519205A
(ja)
|
2000-06-28 |
2004-07-02 |
アムジェン インコーポレイテッド |
胸腺間質リンホポイエチンレセプター分子およびその使用
|
US6989247B2
(en)
|
2000-11-28 |
2006-01-24 |
Celltech R & D, Inc. |
Compositions and methods for diagnosing or treating psoriasis
|
JP4236925B2
(ja)
|
2000-11-28 |
2009-03-11 |
アムジエン・インコーポレーテツド |
免疫応答に関与する新規ポリペプチド
|
US7087726B2
(en)
|
2001-02-22 |
2006-08-08 |
Genentech, Inc. |
Anti-interferon-α antibodies
|
AUPR546801A0
(en)
|
2001-06-05 |
2001-06-28 |
Commonwealth Scientific And Industrial Research Organisation |
Recombinant antibodies
|
SG2011076551A
(en)
|
2001-06-26 |
2015-08-28 |
Amgen Inc |
Antibodies to opgl
|
AU2002335657A1
(en)
|
2001-08-24 |
2003-03-10 |
Neuronz Biosciences, Inc. |
Neural regeneration peptide and methods for their use in treatment of brain damage
|
ES2386346T3
(es)
|
2001-08-29 |
2012-08-17 |
Genentech, Inc. |
Ácidos nucleicos y polipéptidos Bv8 con actividad mitógena
|
US7459432B2
(en)
|
2001-09-24 |
2008-12-02 |
Imperial College Innovations Ltd. |
Modification of feeding behavior
|
EP1501866A4
(en)
|
2001-10-02 |
2006-02-08 |
Genentech Inc |
VARIANTS OF THE LIGAND APO-2 AND USES THEREOF
|
US7521053B2
(en)
|
2001-10-11 |
2009-04-21 |
Amgen Inc. |
Angiopoietin-2 specific binding agents
|
US7138370B2
(en)
|
2001-10-11 |
2006-11-21 |
Amgen Inc. |
Specific binding agents of human angiopoietin-2
|
EP1439857B1
(en)
|
2001-10-12 |
2009-02-25 |
Schering Corporation |
USE OF BISPECIFIC ANTIBODIES BINDING TO THE ACTIVATING RECEPTOR FcEpsilonRI AND TO THE INHIBITING RECEPTOR OX2Ra (CD200Ra) TO REGULATE IMMUNE RESPONSES
|
WO2003042344A2
(en)
|
2001-11-13 |
2003-05-22 |
Genentech, Inc. |
Apo2 ligand/trail formulations
|
EP1997829A1
(en)
|
2001-12-21 |
2008-12-03 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
EP2329839B1
(en)
|
2002-01-10 |
2015-09-16 |
Imperial Innovations Limited |
Modification of feeding behavior by GLP-1 and PYY
|
US8058233B2
(en)
|
2002-01-10 |
2011-11-15 |
Oregon Health And Science University |
Modification of feeding behavior using PYY and GLP-1
|
US7662924B2
(en)
|
2002-02-22 |
2010-02-16 |
The Board Of Trustees Of The University Of Illinois |
Beta chain-associated regulator of apoptosis
|
PL375041A1
(en)
|
2002-04-05 |
2005-11-14 |
Amgen Inc. |
Human anti-opgl neutralizing antibodies as selective opgl pathway inhibitors
|
WO2003087163A1
(fr)
|
2002-04-15 |
2003-10-23 |
Chugai Seiyaku Kabushiki Kaisha |
Procede d'elaboration d'une banque scdb
|
JP4518941B2
(ja)
|
2002-04-26 |
2010-08-04 |
中外製薬株式会社 |
アゴニスト抗体のスクリーニング方法
|
AU2002304965A1
(en)
|
2002-05-24 |
2003-12-12 |
Zensun (Shanghai) Sci-Tech.Ltd |
Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
|
EP2305710A3
(en)
|
2002-06-03 |
2013-05-29 |
Genentech, Inc. |
Synthetic antibody phage libraries
|
EP1556076A4
(en)
|
2002-06-24 |
2009-07-08 |
Genentech Inc |
APO-2 LIGAND / TRAIL VARIANTS AND ITS USES
|
PL377091A1
(pl)
|
2002-09-06 |
2006-01-23 |
Amgen, Inc. |
Ludzkie monoklonalne przeciwciało przeciw-IL-1R1, o właściwościach terapeutycznych
|
US9809654B2
(en)
|
2002-09-27 |
2017-11-07 |
Vaccinex, Inc. |
Targeted CD1d molecules
|
WO2004034988A2
(en)
|
2002-10-16 |
2004-04-29 |
Amgen Inc. |
Human anti-ifn-ϝ neutralizing antibodies as selective ifn-ϝ pathway inhibitors
|
RU2377253C2
(ru)
|
2002-12-02 |
2009-12-27 |
Амген Фремонт,Инк. |
Антитела, специфичные к фактору некроза опухолей, и их применение
|
CA2511823A1
(en)
|
2002-12-30 |
2004-07-22 |
Amgen Inc. |
Combination therapy with co-stimulatory factors
|
GB0300571D0
(en)
|
2003-01-10 |
2003-02-12 |
Imp College Innovations Ltd |
Modification of feeding behaviour
|
MXPA05007823A
(es)
|
2003-01-24 |
2005-10-18 |
Elan Pharm Inc |
Composicion y tratamiento de enfermedades desmielizantes y paralisis por administracion de agentes remielinizantes.
|
KR101294959B1
(ko)
|
2003-03-12 |
2013-08-09 |
제넨테크, 인크. |
조혈을 촉진하기 위한 bv8 및(또는) eg-vegf의 용도
|
ES2557769T3
(es)
|
2003-03-19 |
2016-01-28 |
Amgen Fremont Inc. |
Anticuerpos contra el antígeno del dominio de inmunoglobulina de células T y el dominio 1 de mucina (TIM-1) y usos de los mismos
|
US7375076B2
(en)
|
2003-05-20 |
2008-05-20 |
The Regents Of The University Of Michigan |
Methods of reducing vascular permeability in tissue by inhibition of tissue plasminogen activator (tPA) and tPA inhibitors useful therein
|
CA2530172A1
(en)
|
2003-06-27 |
2005-02-10 |
Abgenix, Inc. |
Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
|
MEP31408A
(en)
|
2003-07-18 |
2010-10-10 |
Abgenix Inc |
Specific binding agents to hepatocyte growth factor
|
HUE027218T2
(en)
|
2003-09-12 |
2016-10-28 |
Ipsen Biopharmaceuticals Inc |
Methods for Treatment of IGF-1 (Insulin-like Growth Factor 1) Deficiency
|
WO2005035753A1
(ja)
|
2003-10-10 |
2005-04-21 |
Chugai Seiyaku Kabushiki Kaisha |
機能蛋白質を代替する二重特異性抗体
|
US20080075712A1
(en)
|
2003-10-14 |
2008-03-27 |
Kunihiro Hattori |
Double Specific Antibodies Substituting For Functional Proteins
|
EP1684791A4
(en)
|
2003-10-27 |
2009-07-01 |
Amgen Inc |
COMPOSITIONS AND METHODS FOR MODULATION OF IMMUNE REACTION TO AN IMMUNOGENIC THERAPEUTIC AGENT
|
CN103755800B
(zh)
|
2004-02-02 |
2016-02-24 |
Ambrx公司 |
经修饰的人类生长激素多肽与其用途
|
JP4996261B2
(ja)
|
2004-02-06 |
2012-08-08 |
エラン ファーマシューティカルズ,インコーポレイテッド |
腫瘍および転移性疾患を処置するための方法および組成物
|
US7807176B2
(en)
|
2004-03-19 |
2010-10-05 |
Genomidea, Inc. |
Polypeptide promoting vascular endothelial cell growth
|
CA2564989C
(en)
|
2004-03-19 |
2014-05-27 |
Amgen, Inc. |
Reducing the risk of human and anti-human antibodies through v gene manipulation
|
MY162179A
(en)
|
2004-04-01 |
2017-05-31 |
Elan Pharm Inc |
Steroid sparing agents and methods of using same
|
EP1598428A1
(en)
|
2004-05-18 |
2005-11-23 |
Georg Dewald |
Methods and kits to detect Hereditary angioedema type III
|
WO2005115992A1
(en)
|
2004-05-23 |
2005-12-08 |
Housey Pharmaceuticals, Inc. |
Theramutein modulators
|
WO2005115438A1
(en)
|
2004-05-25 |
2005-12-08 |
Stryker Corporation |
Use of morphogenic proteins for treating cartilage defects
|
BRPI0512235A
(pt)
|
2004-06-18 |
2008-02-19 |
Ambrx Inc |
polipeptìdeos ligadores de antìgenos e seus usos
|
US20100098663A2
(en)
|
2004-06-22 |
2010-04-22 |
The Board Of Trustees Of The University Of Illinois |
Methods of Inhibiting Tumor Cell Proliferation with FoxM1 siRNA
|
KR101239542B1
(ko)
|
2004-06-24 |
2013-03-07 |
바이오겐 아이덱 엠에이 인코포레이티드 |
탈수초화를 수반하는 병의 치료
|
ME00226B
(me)
|
2004-07-15 |
2011-02-10 |
Medarex Llc |
Humana anti-ngf neutrališuća antitijela kao selektivni inhibitori ngf signalne kaskade
|
CA2576193A1
(en)
|
2004-08-03 |
2006-02-16 |
Biogen Idec Ma Inc. |
Taj in neuronal function
|
EP1786837B1
(en)
|
2004-08-04 |
2013-05-01 |
Amgen Inc., |
Antibodies to dkk-1
|
CN101106997A
(zh)
|
2004-08-17 |
2008-01-16 |
约翰·霍普金斯大学 |
Pde5抑制剂组合物及治疗心脏病征候的方法
|
CN101072580B
(zh)
|
2004-10-06 |
2012-08-22 |
农业生物技术有限公司 |
抗体制备方法
|
EP1810687A4
(en)
|
2004-10-15 |
2009-04-01 |
Univ Mie |
MEANS FOR CONTROL OF LIVER REGENERATION / REPAIR
|
WO2006055638A2
(en)
|
2004-11-17 |
2006-05-26 |
Abgenix, Inc. |
Fully human monoclonal antibodies to il-13
|
EP1827446A4
(en)
|
2004-12-06 |
2011-01-12 |
Siga Technologies Inc |
SULFONYL SEMICARBAZIDES, SEMICARBAZIDES AND URETINS, PHARMACEUTICAL COMPOSITIONS THEREOF AND METHOD FOR TREATING HEMORRHAGIC FEVER VIRUSES, INCLUDING INFECTIONS WITH ARENA VIRUSES
|
WO2006068975A2
(en)
|
2004-12-20 |
2006-06-29 |
Abgenix, Inc. |
Binding proteins specific for human matriptase
|
RS52036B
(en)
|
2004-12-21 |
2012-04-30 |
Medimmune Limited |
ANGIOPOETIN-2 ANTIBODIES AND ITS USES
|
US7638491B2
(en)
|
2004-12-22 |
2009-12-29 |
Ambrx, Inc. |
Therapies using non-natural amino acids and polypeptides
|
CN103690936A
(zh)
|
2004-12-22 |
2014-04-02 |
Ambrx公司 |
经修饰的人类生长激素
|
WO2006081139A2
(en)
|
2005-01-26 |
2006-08-03 |
Abgenix, Inc. |
Antibodies against interleukin-1 beta
|
TW200714313A
(en)
|
2005-04-08 |
2007-04-16 |
Chugai Pharmaceutical Co Ltd |
Antibodies that substitute for coagulation factor VIII
|
US20080009546A1
(en)
|
2005-05-06 |
2008-01-10 |
Chevron U.S.A. Inc. |
Diamondoid derivatives possessing therapeutic activity in the treatment of neurologic disorders
|
WO2006124699A2
(en)
|
2005-05-12 |
2006-11-23 |
Wisconsin Alumni Research Foundation |
Blockade of pin1 prevents cytokine production by activated immune cells
|
US8431110B2
(en)
|
2005-05-23 |
2013-04-30 |
Hmi Medical Innovations, Llc. |
Compounds and method of identifying, synthesizing, optimizing and profiling protein modulators
|
EP1908482B1
(en)
|
2005-06-10 |
2017-09-06 |
Chugai Seiyaku Kabushiki Kaisha |
Stabilizer for protein preparation comprising meglumine and use thereof
|
TW200718780A
(en)
|
2005-06-10 |
2007-05-16 |
Chugai Pharmaceutical Co Ltd |
Sc(Fv)2 site-directed mutant
|
EP3673919A1
(en)
|
2005-06-14 |
2020-07-01 |
Amgen Inc. |
Self-buffering protein formulations
|
SI2163562T1
(sl)
|
2005-06-21 |
2014-01-31 |
Xoma (Us) Llc |
IL-1 beta vezavna protitelesa in njihovi fragmenti
|
EP2238986A3
(en)
|
2005-07-08 |
2010-11-03 |
Biogen Idec MA Inc. |
Sp35 antibodies and uses thereof
|
KR101263079B1
(ko)
|
2005-07-18 |
2013-05-09 |
암젠 인크 |
인간 항-b7rp1 중화 항체
|
WO2007014327A2
(en)
|
2005-07-27 |
2007-02-01 |
University Of Florida Research Foundation, Inc. |
Small compounds that correct protein misfolding and uses thereof
|
JP5905184B2
(ja)
|
2005-10-13 |
2016-04-20 |
ヒューマン ジノーム サイエンシーズ, インコーポレイテッドHuman Genome Sciences, Inc. |
自己抗体陽性疾患を有する患者の処置に使用するための方法および組成物
|
CA2625773C
(en)
|
2005-10-14 |
2015-05-12 |
Fukuoka University |
Inhibition of interleukin-6 (il-6) receptor promotes pancreatic islet transplantation
|
US8945558B2
(en)
|
2005-10-21 |
2015-02-03 |
Chugai Seiyaku Kabushiki Kaisha |
Methods for treating myocardial infarction comprising administering an IL-6 inhibitor
|
NZ568705A
(en)
|
2005-11-04 |
2012-07-27 |
Biogen Idec Inc |
Methods for promoting neurite outgrowth and survival of dopaminergic neurons
|
EP2548583A3
(en)
|
2005-11-10 |
2013-02-27 |
Curagen Corporation |
Method of treating ovarian and renal cancer using antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen
|
TW200736277A
(en)
|
2005-11-14 |
2007-10-01 |
Amgen Inc |
RANKL antibody-PTH/PTHrP chimeric molecules
|
EP1964574B1
(en)
|
2005-11-14 |
2016-09-07 |
Cellmid Limited |
Method for treatment or prevention of disease associated with functional disorder of regulatory t cell
|
AR057582A1
(es)
|
2005-11-15 |
2007-12-05 |
Nat Hospital Organization |
Agentes para suprimir la induccion de linfocitos t citotoxicos
|
JP2009520949A
(ja)
|
2005-11-16 |
2009-05-28 |
アンブルックス,インコーポレイテッド |
非天然アミノ酸を含んでいる組成物および方法
|
AR057941A1
(es)
|
2005-11-25 |
2007-12-26 |
Univ Keio |
Agentes terapeuticos para el cancer de prostata
|
JP5312039B2
(ja)
|
2005-12-02 |
2013-10-09 |
バイオジェン・アイデック・エムエイ・インコーポレイテッド |
脱髄の関与する状態の処置
|
US20070213264A1
(en)
|
2005-12-02 |
2007-09-13 |
Mingdong Zhou |
Neuregulin variants and methods of screening and using thereof
|
WO2008024128A2
(en)
|
2005-12-05 |
2008-02-28 |
Simon Delagrave |
Loop-variant pdz domains as biotherapeutics, diagnostics and research reagents
|
PT1979001E
(pt)
|
2005-12-13 |
2012-07-13 |
Medimmune Ltd |
Proteínas de ligação específicas para factores de crescimento insulínicos e suas aplicações
|
CA2633211A1
(en)
|
2005-12-15 |
2007-06-21 |
Astrazeneca Ab |
Combination of angiopoietin-2 antagonist and of vegf-a, kdr and/or flt1 antagonist for treating cancer
|
CA2841386A1
(en)
|
2005-12-30 |
2007-07-12 |
Zensun (Shanghai) Science & Technology Limited |
Extended release of neuregulin for improved cardiac function
|
JPWO2007083644A1
(ja)
|
2006-01-17 |
2009-06-11 |
ディナベック株式会社 |
新規タンパク質発現系
|
DK1981902T3
(en)
|
2006-01-27 |
2015-10-05 |
Biogen Ma Inc |
Nogo Receptor Antagonists
|
AR059213A1
(es)
|
2006-01-27 |
2008-03-19 |
Univ Keio |
Agentes terapeuticos para enfermedades que involucran neovascularizacion coroidal
|
JP5754875B2
(ja)
|
2006-04-07 |
2015-07-29 |
国立大学法人大阪大学 |
筋再生促進剤
|
TW200813091A
(en)
|
2006-04-10 |
2008-03-16 |
Amgen Fremont Inc |
Targeted binding agents directed to uPAR and uses thereof
|
CA2652549A1
(en)
|
2006-05-17 |
2007-12-13 |
Stryker Corporation |
Use of a soluble morphogenic protein complex for treating cartilage defects
|
ES2429225T3
(es)
|
2006-05-17 |
2013-11-13 |
The Ludwig Institute For Cancer Research |
Anticuerpos anti VEGF-B para tratamiento o profilaxis de diabetes de tipo II o síndrome metabólico
|
US8124743B2
(en)
|
2006-06-01 |
2012-02-28 |
President And Fellows Of Harvard College |
Purification of a bivalently active antibody using a non-chromatographic method
|
EP2047863B1
(en)
|
2006-06-08 |
2013-07-31 |
Chugai Seiyaku Kabushiki Kaisha |
Preventive or remedy for inflammatory disease
|
KR20090038896A
(ko)
|
2006-07-13 |
2009-04-21 |
추가이 세이야쿠 가부시키가이샤 |
세포사 유도제
|
EP2574625B1
(en)
|
2006-07-21 |
2015-02-25 |
HuBit genomix, Inc. |
Remedy for renal disease
|
AU2007279205B2
(en)
|
2006-07-28 |
2013-09-26 |
Children's Memorial Hospital |
Methods of inhibiting tumor cell aggressiveness using the microenvironment of human embryonic stem cells
|
CL2007002225A1
(es)
|
2006-08-03 |
2008-04-18 |
Astrazeneca Ab |
Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
|
US9505823B2
(en)
|
2006-08-07 |
2016-11-29 |
TEV A Biopharmaceuticals USA, Inc. |
Albumin-insulin fusion proteins
|
CN106008699A
(zh)
|
2006-09-08 |
2016-10-12 |
Ambrx公司 |
经修饰的人类血浆多肽或Fc骨架和其用途
|
US7833527B2
(en)
|
2006-10-02 |
2010-11-16 |
Amgen Inc. |
Methods of treating psoriasis using IL-17 Receptor A antibodies
|
RU2447449C2
(ru)
|
2006-11-14 |
2012-04-10 |
Дженентек, Инк. |
Модуляторы нейрональной регенерации
|
ZA200904022B
(en)
|
2006-12-08 |
2010-08-25 |
Lexicon Pharmaceuticals Inc |
Monoclonal antibodies against ANGPTL3
|
TWI428346B
(zh)
|
2006-12-13 |
2014-03-01 |
Imp Innovations Ltd |
新穎化合物及其等對進食行為影響
|
AU2007333635B2
(en)
|
2006-12-20 |
2014-02-20 |
Xoma (Us) Llc |
Treatment of IL-1-beta related diseases
|
WO2008086006A2
(en)
|
2007-01-09 |
2008-07-17 |
Biogen Idec Ma Inc. |
Sp35 antibodies and uses thereof
|
CN101646459B
(zh)
|
2007-01-23 |
2014-02-12 |
国立大学法人信州大学 |
慢性排斥反应抑制剂
|
KR20090123873A
(ko)
|
2007-02-02 |
2009-12-02 |
바이오겐 아이덱 엠에이 인코포레이티드 |
수초형성 및 올리고덴드로사이트 분화 촉진을 위한 세마포린 6a의 용도
|
TWI573802B
(zh)
|
2007-03-06 |
2017-03-11 |
安美基公司 |
變異之活動素受體多肽及其用途
|
US8501678B2
(en)
|
2007-03-06 |
2013-08-06 |
Atara Biotherapeutics, Inc. |
Variant activin receptor polypeptides and uses thereof
|
CL2008000719A1
(es)
|
2007-03-12 |
2008-09-05 |
Univ Tokushima Chugai Seiyaku |
Agente terapeutico para cancer resistente a agentes quimioterapeuticos que comprende un anticuerpo que reconoce hla de clase i como ingrediente activo; composicion farmaceutica que comprende dicho anticuerpo; y metodo para tratar cancer resistente a
|
CA2682147C
(en)
|
2007-03-30 |
2017-08-08 |
Ambrx, Inc. |
Modified fgf-21 polypeptides and their uses
|
US20110065673A1
(en)
|
2007-05-11 |
2011-03-17 |
Bizen Chemical Co., Ltd. |
Novel leukotriene receptor agonist
|
EP1995227A1
(en)
|
2007-05-24 |
2008-11-26 |
Chevron USA, Inc. |
Spiro and other derivatives of diamondoids posessing therapeutic activity in the treatment of viral disorders
|
EP1994927A1
(en)
|
2007-05-24 |
2008-11-26 |
Chevron USA, Inc. |
Diamondoid derivatives possessing therapeutic activity in the treatment of viral disorders
|
US20110206673A1
(en)
|
2007-06-27 |
2011-08-25 |
Liu Dongxu |
Polypeptides and polynucleotides for artemin and related ligands, and methods of use thereof
|
JP5424330B2
(ja)
|
2007-07-26 |
2014-02-26 |
国立大学法人大阪大学 |
インターロイキン6受容体阻害剤を有効成分とする眼炎症疾患治療剤
|
TWI595005B
(zh)
|
2007-08-21 |
2017-08-11 |
安健股份有限公司 |
人類c-fms抗原結合蛋白質
|
JOP20080381B1
(ar)
|
2007-08-23 |
2023-03-28 |
Amgen Inc |
بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
|
EP2615113A3
(en)
|
2007-08-23 |
2013-11-13 |
Amgen Inc. |
Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
|
US7982016B2
(en)
|
2007-09-10 |
2011-07-19 |
Amgen Inc. |
Antigen binding proteins capable of binding thymic stromal lymphopoietin
|
US20090156488A1
(en)
|
2007-09-12 |
2009-06-18 |
Zensun (Shanghai) Science & Technology Limited |
Use of neuregulin for organ preservation
|
TW200918553A
(en)
|
2007-09-18 |
2009-05-01 |
Amgen Inc |
Human GM-CSF antigen binding proteins
|
EP2040075A1
(en)
|
2007-09-24 |
2009-03-25 |
Julius-Maximilians-Universität Würzburg |
Compounds and markers for surface-enhanced raman scattering
|
SG187477A1
(en)
|
2007-09-26 |
2013-02-28 |
U3 Pharma Gmbh |
Heparin-binding epidermal growth factor-like growth factor antigen binding proteins
|
MX2010003139A
(es)
|
2007-10-02 |
2010-04-07 |
Chugai Pharmaceutical Co Ltd |
Agentes terapeuticos para la enfermedad de injerto contra hospedero que comprenden un inhibidor del receptor de interleucina 6 como ingrediente activo.
|
JP5616230B2
(ja)
|
2007-11-16 |
2014-10-29 |
ザ ロックフェラー ユニバーシティー |
ベータ−アミロイドタンパク質のプロトフィブリルの形態に特異的な抗体
|
NZ603812A
(en)
|
2007-11-20 |
2014-06-27 |
Ambrx Inc |
Modified insulin polypeptides and their uses
|
ES2585480T3
(es)
|
2007-12-05 |
2016-10-06 |
Chugai Seiyaku Kabushiki Kaisha |
Anticuerpo anti-NR10 y uso del mismo
|
CN104162155A
(zh)
|
2007-12-05 |
2014-11-26 |
中外制药株式会社 |
搔痒症治疗药
|
EP2241333A1
(en)
|
2007-12-12 |
2010-10-20 |
National Cancer Center |
Therapeutic agent for mll leukemia and moz leukemia of which molecular target is m-csf receptor, and use thereof
|
PL2391650T3
(pl)
|
2007-12-20 |
2015-03-31 |
Xoma Us Llc |
Sposoby leczenia dny
|
MX2010008632A
(es)
|
2008-02-08 |
2010-08-30 |
Ambrx Inc |
Leptina-polipeptidos modificados y sus usos.
|
JO2913B1
(en)
|
2008-02-20 |
2015-09-15 |
امجين إنك, |
Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
|
JOP20190083A1
(ar)
|
2008-06-04 |
2017-06-16 |
Amgen Inc |
بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
|
KR101665729B1
(ko)
|
2008-06-05 |
2016-10-12 |
국립연구개발법인 고쿠리츠간켄큐센터 |
신경침윤 억제제
|
PL2684873T3
(pl)
|
2008-06-09 |
2019-07-31 |
Ludwig-Maximilians-Universität München |
Leki do hamowania agregacji białek związanych z chorobami związanymi z agregacją białka i/lub chorobami neurodegeneracyjnymi
|
CA2729012A1
(en)
|
2008-06-27 |
2009-12-30 |
Amgen Inc. |
Ang-2 inhibition to treat multiple sclerosis
|
US8058406B2
(en)
|
2008-07-09 |
2011-11-15 |
Biogen Idec Ma Inc. |
Composition comprising antibodies to LINGO or fragments thereof
|
EP2318029B1
(en)
|
2008-07-23 |
2017-11-01 |
Ambrx, Inc. |
Modified bovine g-csf polypeptides and their uses
|
KR20110051245A
(ko)
|
2008-09-10 |
2011-05-17 |
제넨테크, 인크. |
안구 혈관신생의 억제 방법
|
WO2010032060A1
(en)
|
2008-09-19 |
2010-03-25 |
Medimmune Llc |
Antibodies directed to dll4 and uses thereof
|
KR101647164B1
(ko)
|
2008-09-26 |
2016-08-09 |
암브룩스, 인코포레이티드 |
변형된 동물 에리트로포이에틴 폴리펩티드 및 이의 용도
|
CA2738033C
(en)
|
2008-09-26 |
2019-11-26 |
Ambrx, Inc. |
Non-natural amino acid replication-dependent microorganisms and vaccines
|
WO2010042747A2
(en)
|
2008-10-10 |
2010-04-15 |
Amgen Inc. |
Fgf21 mutants and uses thereof
|
CA2739663A1
(en)
|
2008-10-10 |
2010-05-15 |
Anaphore, Inc. |
Polypeptides that bind trail-r1 and trail-r2
|
CN102307593B
(zh)
|
2008-10-22 |
2016-04-13 |
弗·哈夫曼-拉罗切有限公司 |
轴突变性的调节
|
KR101778134B1
(ko)
|
2008-11-26 |
2017-09-13 |
암젠 인크 |
액티빈 iib 수용체 폴리펩타이드의 변이체 및 이의 용도
|
US20120087870A1
(en)
|
2008-12-19 |
2012-04-12 |
Hentges Francois |
Novel caviidae allergens and uses thereof
|
EP2367564A1
(en)
|
2008-12-22 |
2011-09-28 |
Universität Regensburg |
Norrin in the treatment of diseases associated with an increased tgf-beta activity
|
JO3382B1
(ar)
|
2008-12-23 |
2019-03-13 |
Amgen Inc |
أجسام مضادة ترتبط مع مستقبل cgrp بشري
|
AU2009331528A1
(en)
|
2008-12-23 |
2011-08-11 |
Astrazeneca Ab |
Targeted binding agents directed to alpha5beta1 and uses thereof
|
KR20110137290A
(ko)
|
2009-01-08 |
2011-12-22 |
알버트 아인슈타인 컬리지 오브 메디신 오브 예쉬바 유니버시티 |
세포벽 결합 세라미드 유사 당지질을 갖는 박테리아 백신 및 이의 용도
|
EP2390261A4
(en)
|
2009-01-20 |
2012-11-14 |
Hanall Biopharma Co Ltd |
MODIFIED HUMAN THROMBOPOIETIN POLYPEPTIDE FRAGMENT AND METHOD FOR THE PRODUCTION THEREOF
|
EP2396035A4
(en)
|
2009-02-12 |
2012-09-12 |
Human Genome Sciences Inc |
USE OF ANTAGONISTS OF PROTEIN STIMULATING LYMPHOCYTES B TO PROMOTE GRAFT TOLERANCE
|
WO2010092109A2
(en)
|
2009-02-13 |
2010-08-19 |
Novartis Ag |
Nucleic acid molecule of a biosynthetic cluster encoding non ribosomal peptide synthases and uses thereof
|
WO2010099166A1
(en)
|
2009-02-27 |
2010-09-02 |
Siga Technologies, Inc. |
Thienopyridine derivatives for the treatment and prevention of dengue virus infections
|
JP2010210772A
(ja)
|
2009-03-13 |
2010-09-24 |
Dainippon Screen Mfg Co Ltd |
液晶表示装置の製造方法
|
US9724337B2
(en)
|
2009-04-21 |
2017-08-08 |
University Of Kentucky Research Foundation |
AG-205 for the treatment of breast cancer
|
EP2427207B1
(en)
|
2009-05-05 |
2017-08-16 |
Amgen, Inc |
Fgf21 mutants and uses thereof
|
PE20160718A1
(es)
|
2009-05-05 |
2016-08-03 |
Amgen Inc |
Polipeptidos mutantes fgf21
|
EP2260857A1
(en)
|
2009-06-11 |
2010-12-15 |
Alfact Innovation |
Novel applications of HIP/PAP or derivatives thereof
|
IN2012DN00352A
(xx)
|
2009-06-16 |
2015-08-21 |
Bikam Pharmaceuticals Inc |
|
MX2011013903A
(es)
|
2009-06-17 |
2012-05-08 |
Amgen Inc |
Polipeptidos quimericos y usos de los mismos.
|
EP2460538B1
(en)
|
2009-07-31 |
2017-09-13 |
Shin Maeda |
Cancer metastasis inhibitor
|
TW201118166A
(en)
|
2009-09-24 |
2011-06-01 |
Chugai Pharmaceutical Co Ltd |
HLA class I-recognizing antibodies
|
EP2305285A1
(en)
|
2009-09-29 |
2011-04-06 |
Julius-Maximilians-Universität Würzburg |
Means and methods for treating ischemic conditions
|
EP2305810A1
(en)
|
2009-10-02 |
2011-04-06 |
Technische Universität München |
miRNAs in the treatment of fibrosis
|
TW201117824A
(en)
|
2009-10-12 |
2011-06-01 |
Amgen Inc |
Use of IL-17 receptor a antigen binding proteins
|
EP2488186B1
(en)
|
2009-10-16 |
2017-05-24 |
National University of Singapore |
Anti-neoplastic uses of artemin antagonists
|
JP5746191B2
(ja)
|
2009-10-19 |
2015-07-08 |
ハナル バイオファーマ カンパニーリミテッドHanAll Biopharma Co., Ltd. |
修飾されたヒト腫瘍壊死因子受容体−1ポリペプチドまたはその断片及びその製造方法
|
EP3011970A3
(en)
|
2009-10-22 |
2016-06-08 |
F. Hoffmann-La Roche AG |
Modulation of axon degeneration
|
SI3202898T1
(sl)
|
2009-11-02 |
2019-04-30 |
University of Washington Center for Commercialization |
Terapevtski sestavki nukleaze in postopki
|
WO2011060372A2
(en)
|
2009-11-13 |
2011-05-19 |
Puget Sound Blood Center |
Factor viii b cell epitope variants having reduced immunogenicity
|
RU2571204C3
(ru)
|
2009-11-24 |
2020-12-14 |
Медиммьюн Лимитед |
Специфические связывающие агенты против в7-н1
|
EP2679234A3
(en)
|
2009-12-02 |
2014-04-23 |
Amgen Inc. |
Binding proteins that bind to human FGFR1C, human beta-klotho and both human FGFR1C and human beta-klotho
|
US8491927B2
(en)
|
2009-12-02 |
2013-07-23 |
Nimble Epitech, Llc |
Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor
|
UA109888C2
(uk)
|
2009-12-07 |
2015-10-26 |
|
ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
|
PE20121707A1
(es)
|
2009-12-21 |
2012-12-17 |
Ambrx Inc |
Polipeptidos de somatotropina bovina modificados y sus usos
|
CN102666578A
(zh)
|
2009-12-21 |
2012-09-12 |
Ambrx公司 |
经过修饰的猪促生长素多肽和其用途
|
US20130053438A1
(en)
|
2010-01-19 |
2013-02-28 |
Universitat Innsbruck |
Pharmaceutical compositions comprising lignans and their derivatives for the medical management of angiogenesis and hypovascularity
|
EP2528938A4
(en)
|
2010-01-27 |
2013-10-23 |
Childrens Medical Center |
PROANGIOGENIC FRAGMENTS OF PROMININ 1 AND USES THEREOF
|
WO2011099007A1
(en)
|
2010-02-10 |
2011-08-18 |
Nayacure Therapeutics Ltd. |
Pharmaceutical compositions and methods for the treatment and prevention of cancer
|
EP2536286A4
(en)
|
2010-02-19 |
2013-11-13 |
Siga Technologies Inc |
INHIBITORS AND METHOD FOR INHIBITING BACTERIAL AND VIRAL DISEASES
|
WO2011118804A1
(ja)
|
2010-03-26 |
2011-09-29 |
国立大学法人徳島大学 |
新規抗cd98抗体とその用途
|
WO2011119906A1
(en)
|
2010-03-26 |
2011-09-29 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
HUMAN POLYOMAVIRUS 6 (HPyV6) AND HUMAN POLYOMAVIRUS 7 (HPyV7)
|
WO2011130417A2
(en)
|
2010-04-15 |
2011-10-20 |
Amgen Inc. |
HUMAN FGF RECEPTOR AND β-KLOTHO BINDING PROTEINS
|
WO2011131626A1
(en)
|
2010-04-19 |
2011-10-27 |
Medizinische Universität Innsbruck |
Tmem195 encodes for tetrahydrobiopterin-dependent alkylglycerol monooxygenase activity
|
WO2011139594A2
(en)
|
2010-04-27 |
2011-11-10 |
Medtronic, Inc. |
Artificial bursa for intra-articular drug delivery
|
WO2011139595A2
(en)
|
2010-04-27 |
2011-11-10 |
Medtronic, Inc. |
Elongated biodegradable depot for sustained drug release to treat chronic pelvic pain
|
EP3181692A1
(en)
|
2010-05-07 |
2017-06-21 |
Centre National De La Recherche Scientifique |
Ucp1 (thermogenin) - inducing agents for use in the treatment of a disorder of the energy homeostasis
|
US9273316B2
(en)
|
2010-05-21 |
2016-03-01 |
Peptimed, Inc. |
Reagents and methods for treating cancer
|
WO2011149046A1
(ja)
|
2010-05-28 |
2011-12-01 |
独立行政法人国立がん研究センター |
膵癌治療剤
|
EP2578231B1
(en)
|
2010-05-28 |
2022-10-26 |
Chugai Seiyaku Kabushiki Kaisha |
Antitumor t cell response enhancer
|
RU2012157399A
(ru)
|
2010-06-18 |
2014-07-27 |
КсайберСайенс ГмбХ |
Пептиды в качестве активных агентов для стабилизации биологических барьеров
|
RS59193B1
(sr)
|
2010-08-17 |
2019-10-31 |
Ambrx Inc |
Modifikovani polipeptidi relaksina i njihova primena
|
US9567386B2
(en)
|
2010-08-17 |
2017-02-14 |
Ambrx, Inc. |
Therapeutic uses of modified relaxin polypeptides
|
TWI480288B
(zh)
|
2010-09-23 |
2015-04-11 |
Lilly Co Eli |
牛顆粒細胞群落刺激因子及其變體之調配物
|
DK2623592T3
(da)
|
2010-09-28 |
2019-08-19 |
Nb Health Laboratory Co Ltd |
Anti-humane ccr7-antistoffer, hybridom, medicinsk sammensætning og antistof-immobiliseret bærer
|
MX2013004679A
(es)
|
2010-10-25 |
2014-02-20 |
Univ Minnesota |
Composicion terapeutica para el tratamiento de glioblastoma.
|
TWI636994B
(zh)
|
2010-10-27 |
2018-10-01 |
安美基公司 |
Dkk1抗體及使用方法
|
JP6189215B2
(ja)
|
2010-11-01 |
2017-08-30 |
ペプチメッド, インコーポレイテッド |
細胞特異的ターゲティングのためのペプチドに基づいたシステムの組成物
|
KR102099580B1
(ko)
|
2010-11-17 |
2020-04-10 |
추가이 세이야쿠 가부시키가이샤 |
혈액응고 제viii 인자의 기능을 대체하는 기능을 갖는 다중특이성 항원 결합 분자
|
US9023791B2
(en)
|
2010-11-19 |
2015-05-05 |
Novartis Ag |
Fibroblast growth factor 21 mutations
|
BR112013012858B1
(pt)
|
2010-11-24 |
2021-12-07 |
Lexicon Pharmaceuticals, Inc |
Anticorpo monoclonal que se liga a pectinacetilesterase de notum, composição farmacêutica, molécula de ácido nucleico, célula hospedeira e método para produzir o dito anticorpo
|
WO2012073985A1
(ja)
|
2010-11-30 |
2012-06-07 |
中外製薬株式会社 |
細胞傷害誘導治療剤
|
WO2012075048A2
(en)
|
2010-11-30 |
2012-06-07 |
The Johns Hopkins University |
Hybrid cyclic libraries and screens thereof
|
JP5819439B2
(ja)
|
2010-12-23 |
2015-11-24 |
ハノル バイオファーマ カンパニー リミテッド |
修飾されたヒト腫瘍壊死因子受容体−1ポリペプチドまたはその断片及びその製造方法
|
WO2012092539A2
(en)
|
2010-12-31 |
2012-07-05 |
Takeda Pharmaceutical Company Limited |
Antibodies to dll4 and uses thereof
|
SG10201600531TA
(en)
|
2011-01-24 |
2016-02-26 |
Univ Singapore |
Pathogenic mycobacteria-derived mannose-capped lipoarabinomannan antigen binding proteins
|
JP6348283B2
(ja)
|
2011-01-27 |
2018-06-27 |
ニューレン ファーマシューティカルズ リミテッド |
グリシル−l−2−メチルプロリル−l−グルタミン酸を用いる自閉症スペクトラム障害の治療
|
CA2828000A1
(en)
|
2011-03-01 |
2012-09-07 |
Amgen Inc. |
Bispecific binding agents
|
EP2683368A1
(en)
|
2011-03-10 |
2014-01-15 |
F.Hoffmann-La Roche Ag |
Treatment of disorders with altered vascular barrier function
|
US10059746B2
(en)
|
2011-04-04 |
2018-08-28 |
University Of Iowa Research Foundation |
Methods of improving vaccine immunogenicity
|
EP2694552B1
(en)
|
2011-04-07 |
2017-10-11 |
Amgen Inc. |
Novel egfr binding proteins
|
CA2832581C
(en)
|
2011-04-08 |
2022-08-23 |
Yumei Xiong |
Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
|
HUE038759T2
(hu)
|
2011-04-29 |
2018-11-28 |
Univ Washington |
Terápiás nukleázkészítmények és eljárások
|
CA2834776A1
(en)
|
2011-05-03 |
2012-11-08 |
Genentech, Inc. |
Therapeutic apo2l/trail polypeptides and death receptor agonist antibodies
|
EP2707718A1
(en)
|
2011-05-10 |
2014-03-19 |
Amgen Inc. |
Method of identifying compounds that specifically modulate the interaction of fgfr1 and beta-klotho
|
JOP20200043A1
(ar)
|
2011-05-10 |
2017-06-16 |
Amgen Inc |
طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
|
US9574002B2
(en)
|
2011-06-06 |
2017-02-21 |
Amgen Inc. |
Human antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptor
|
BR112013032199A2
(pt)
|
2011-06-14 |
2017-12-12 |
Bikam Pharmaceuticals Inc |
ligantes de ligação à opsina, composições e métodos de utilização
|
AU2012271329A1
(en)
|
2011-06-17 |
2013-12-19 |
Amgen Inc. |
Method of treating or ameliorating metabolic disorders using Clec-2
|
WO2013016220A1
(en)
|
2011-07-22 |
2013-01-31 |
Amgen Inc. |
Il-17 receptor a is required for il-17c biology
|
WO2013017656A1
(en)
|
2011-08-02 |
2013-02-07 |
Medizinische Universität Wien |
Antagonists of ribonucleases for treating obesity
|
US9328386B2
(en)
|
2011-08-16 |
2016-05-03 |
Evotec (München) Gmbh |
Markers for susceptibility to an inhibitor of an Src-family kinase
|
EP3348575A1
(en)
|
2011-08-16 |
2018-07-18 |
Emory University |
Jaml specific binding agents, antibodies, and uses related thereto
|
US9745288B2
(en)
|
2011-08-16 |
2017-08-29 |
Indiana University Research And Technology Corporation |
Compounds and methods for treating cancer by inhibiting the urokinase receptor
|
AU2012301769B2
(en)
|
2011-08-31 |
2016-05-19 |
Amgen Inc. |
FGF21 for use in treating type 1 diabetes
|
WO2013039916A1
(en)
|
2011-09-12 |
2013-03-21 |
The United States Of America, Represented By The Secretary, Dept. Of Health And Human Services |
Compositions for and methods of treatment and enhanced detection of non-pituitary tumors
|
EP2758437B1
(en)
|
2011-09-22 |
2020-06-03 |
Amgen Inc. |
Cd27l antigen binding proteins
|
TW201315742A
(zh)
|
2011-09-26 |
2013-04-16 |
Novartis Ag |
治療代謝病症之雙功能蛋白質
|
UY34346A
(es)
|
2011-09-26 |
2013-04-30 |
Novartis Ag |
Proteínas de fusión para tratar trastornos metabólicos
|
CN110655578A
(zh)
|
2011-09-30 |
2020-01-07 |
中外制药株式会社 |
诱导针对靶抗原的免疫应答的抗原结合分子
|
WO2013053076A1
(en)
|
2011-10-10 |
2013-04-18 |
Zensun (Shanghai)Science & Technology Limited |
Compositions and methods for treating heart failure
|
US8906860B2
(en)
|
2011-10-14 |
2014-12-09 |
The Board Of Trustees Of The University Of Illinois |
Methods and compositions inhibiting tumor cell proliferation
|
US20130172265A1
(en)
|
2011-10-14 |
2013-07-04 |
The Board Of Trustees Of The University Of Illinois |
Methods and Compositions for Inhibiting Tumor Cell Proliferation
|
US9499464B2
(en)
|
2011-10-19 |
2016-11-22 |
Bikam Pharmaceuticals, Inc. |
Opsin-binding ligands, compositions and methods of use
|
BR112014011912A2
(pt)
|
2011-11-16 |
2017-05-16 |
Amgen Inc |
método para o tratamento de um mamífero que tem um tumor
|
GR1007832B
(el)
|
2011-11-21 |
2013-02-14 |
Ιδρυμα Ιατροβιολογικων Ερευνων Ακαδημιας Αθηνων, |
Αδρανοποιητες της ακτιβινης και χρηση τους για την θεραπεια ασθενειων που σχετιζονται με παρεκκλινουσα ενεργοποιηση της "αμυντικης αποκρισης του ξενιστη"
|
BR112014012997A2
(pt)
|
2011-11-30 |
2017-06-13 |
Bikam Pharmaceuticals Inc |
ligantes que se ligam à opsina, composições e métodos de uso
|
EP2785178B1
(en)
|
2011-12-01 |
2019-05-01 |
Bikam Pharmaceuticals, Inc. |
Opsin-binding ligands, compositions and methods of use
|
EP2601941A1
(en)
|
2011-12-06 |
2013-06-12 |
Ludwig-Maximilians-Universität München |
Beta-O/S/N fatty acid based compounds as antibacterial and antiprotozoal agents
|
JP6635655B2
(ja)
|
2011-12-08 |
2020-01-29 |
アムジエン・インコーポレーテツド |
ヒトlcat抗原結合タンパク質および治療法におけるそれらの使用
|
WO2013083810A1
(en)
|
2011-12-09 |
2013-06-13 |
F. Hoffmann-La Roche Ag |
Identification of non-responders to her2 inhibitors
|
EP2794657B1
(en)
|
2011-12-19 |
2017-10-11 |
Xoma (Us) Llc |
Methods for treating acne
|
CN104379159A
(zh)
|
2011-12-19 |
2015-02-25 |
安姆根公司 |
变体激活素受体多肽,单独或与化疗结合,及其用途
|
CA2862979A1
(en)
|
2012-01-09 |
2013-07-18 |
The Scripps Research Institute |
Humanized antibodies with ultralong cdr3s
|
AU2013208003B2
(en)
|
2012-01-09 |
2017-12-14 |
The Scripps Research Institute |
Ultralong complementarity determining regions and uses thereof
|
WO2013106572A1
(en)
|
2012-01-11 |
2013-07-18 |
Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Arizona State University |
Bispecific antibody fragments for neurological disease proteins and methods of use
|
BR112014018575A2
(pt)
|
2012-01-26 |
2017-07-04 |
Amgen Inc |
polipetídeos de fator de diferenciação de crescimento 15 (gdf-15)
|
EP2626066A1
(en)
|
2012-02-10 |
2013-08-14 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Combination therapy comprising selective VEGFR-2 inhibitors and MEK inhibitors
|
WO2013123215A2
(en)
|
2012-02-17 |
2013-08-22 |
Siga Technologies, Inc. |
Antiviral drugs for treatment of arenavirus infection
|
CN104271772A
(zh)
|
2012-03-29 |
2015-01-07 |
科罗拉多州立大学董事会,公司实体 |
点击核酸
|
CA2871417C
(en)
|
2012-04-23 |
2021-08-31 |
Genefrontier Corporation |
Anti-human cd69 antibody, and use thereof for medical purposes
|
EA039663B1
(ru)
|
2012-05-03 |
2022-02-24 |
Амген Инк. |
Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
|
AR091069A1
(es)
|
2012-05-18 |
2014-12-30 |
Amgen Inc |
Proteinas de union a antigeno dirigidas contra el receptor st2
|
EP2666775A1
(en)
|
2012-05-21 |
2013-11-27 |
Domain Therapeutics |
Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors
|
TW201400446A
(zh)
|
2012-05-22 |
2014-01-01 |
Genentech Inc |
N-取代之苯甲醯胺及其使用方法
|
MX2014013407A
(es)
|
2012-05-22 |
2014-11-26 |
Hoffmann La Roche |
Dipiridilaminas sustituidas y uso de las mismas.
|
US9844582B2
(en)
|
2012-05-22 |
2017-12-19 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with extended-PK IL-2 and therapeutic agents
|
EP2866821B1
(en)
|
2012-07-02 |
2018-11-14 |
Medizinische Universität Wien |
Complement split product c4d for the treatment of inflammatory conditions
|
KR101663436B1
(ko)
|
2012-07-06 |
2016-10-06 |
제넨테크, 인크. |
N-치환된 벤즈아미드 및 이의 사용 방법
|
EP2687225A1
(en)
|
2012-07-19 |
2014-01-22 |
Alfact Innovation |
HIP/PAP protein and derivatives thereof for use in treating cancer
|
EP2695950A1
(en)
|
2012-08-10 |
2014-02-12 |
Blackfield AG |
Markers for responsiveness to an inhibitor of the fibroblast growth factor receptor
|
EP2887942A4
(en)
|
2012-08-21 |
2016-08-31 |
Genesys Res Inst |
COMPOSITIONS AND METHODS FOR TREATMENT OR PREVENTION OF ANTHRACYCLIN-INDUCED CARDIOTOXICITY
|
JP6262743B2
(ja)
|
2012-09-27 |
2018-01-17 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
置換スルホンアミド化合物
|
HUE042262T2
(hu)
|
2012-10-17 |
2019-06-28 |
Vascular Biogenics Ltd |
FAS-kimérát kifejezõ adenovírus és alkalmazása rákkezelési módszerekben
|
US9309318B2
(en)
|
2012-10-17 |
2016-04-12 |
Amgen, Inc. |
Compositions relating to anti-IL-21 receptor antibodies
|
CA2890862C
(en)
|
2012-11-09 |
2021-10-12 |
Genefrontier Corporation |
Anti-adam28 antibody for treating cancer
|
UY35148A
(es)
|
2012-11-21 |
2014-05-30 |
Amgen Inc |
Immunoglobulinas heterodiméricas
|
RU2692773C2
(ru)
|
2012-11-30 |
2019-06-27 |
Ф.Хоффманн-Ля Рош Аг |
Идентификация пациентов, нуждающихся в совместной терапии с использованием ингибитора pd-l1
|
TW201425336A
(zh)
|
2012-12-07 |
2014-07-01 |
Amgen Inc |
Bcma抗原結合蛋白質
|
WO2014111496A1
(en)
|
2013-01-18 |
2014-07-24 |
F. Hoffmann-La Roche Ag |
3-substituted pyrazoles and use as dlk inhibitors
|
JO3519B1
(ar)
|
2013-01-25 |
2020-07-05 |
Amgen Inc |
تركيبات أجسام مضادة لأجل cdh19 و cd3
|
US9920121B2
(en)
|
2013-01-25 |
2018-03-20 |
Amgen Inc. |
Antibodies targeting CDH19 for melanoma
|
MX2015009901A
(es)
|
2013-02-01 |
2016-04-06 |
Santa Maria Biotherapeutics Inc |
Administración de un compuesto de antiactivina a a un sujeto.
|
US9371352B2
(en)
|
2013-02-08 |
2016-06-21 |
Vaccinex, Inc. |
Modified glycolipids and methods of making and using the same
|
US9458246B2
(en)
|
2013-03-13 |
2016-10-04 |
Amgen Inc. |
Proteins specific for BAFF and B7RP1
|
JOP20140087B1
(ar)
|
2013-03-13 |
2021-08-17 |
Amgen Inc |
بروتينات مخصصة ل baff و b7rp1 وإستخداماتها
|
WO2014159764A1
(en)
|
2013-03-14 |
2014-10-02 |
Amgen Inc. |
Chrdl-1 antigen binding proteins and methods of treatment
|
BR112015022488A2
(pt)
|
2013-03-14 |
2017-07-18 |
Genentech Inc |
triazolopiridinas substituídas e métodos de uso das mesmas
|
US9546203B2
(en)
|
2013-03-14 |
2017-01-17 |
Amgen Inc. |
Aglycosylated Fc-containing polypeptides with cysteine substitutions
|
US9850297B2
(en)
|
2013-03-15 |
2017-12-26 |
Amgen Inc. |
Secreted frizzle-related protein 5 (SFRP5) binding proteins
|
EP2970483A2
(en)
|
2013-03-15 |
2016-01-20 |
Amgen Inc. |
Methods and compositions relating to anti-ccr7 antigen binding proteins
|
WO2014140368A1
(en)
|
2013-03-15 |
2014-09-18 |
Amgen Research (Munich) Gmbh |
Antibody constructs for influenza m2 and cd3
|
PT2970449T
(pt)
|
2013-03-15 |
2019-11-06 |
Amgen Res Munich Gmbh |
Moléculas de ligação de cadeia única compreendendo abp n-terminal
|
WO2014144817A2
(en)
|
2013-03-15 |
2014-09-18 |
Amgen Inc. |
Inhibitory polypeptides specific to wnt inhibitors
|
JP6283408B2
(ja)
|
2013-03-15 |
2018-02-21 |
アムジェン インコーポレイテッド |
ヒトpac1抗体
|
WO2014151962A1
(en)
|
2013-03-15 |
2014-09-25 |
Amgen Inc. |
Method of treating metabolic disorders using pla2g12a polypeptides and pla2g12a mutant polypeptides
|
BR112015027381A8
(pt)
|
2013-05-01 |
2018-01-30 |
Hoffmann La Roche |
pirimidinas substituídas por heterocicloalquila ligadas ao c e seus usos
|
EA038235B1
(ru)
|
2013-05-01 |
2021-07-28 |
Ф.Хоффманн-Ля Рош Аг |
Бигетероарильные соединения и их применения
|
WO2014187881A1
(en)
|
2013-05-21 |
2014-11-27 |
Max-Planck Gesellschaft zur Förderung der Wissenschaften e.V. |
Isoforms of gata6 and nkx2-1 as markers for diagnosis and therapy of cancer and as targets for anti-cancer therapy
|
AU2014270882B2
(en)
|
2013-05-22 |
2019-03-14 |
Zensun (Shanghai) Science & Technology, Co. Ltd. |
Extended release of neuregulin for treating heart failure
|
US20160130585A1
(en)
|
2013-05-28 |
2016-05-12 |
The Johns Hopkins University |
Aptamers for the treatment of sickle cell disease
|
CN118271441A
(zh)
|
2013-05-30 |
2024-07-02 |
基尼克萨制药有限公司 |
制瘤素m受体抗原结合蛋白
|
EP2810648A1
(en)
|
2013-06-04 |
2014-12-10 |
Daniel Rauh |
Targeting domain-domain interaction for the identification of kinase modulators
|
WO2014200018A1
(ja)
|
2013-06-11 |
2014-12-18 |
独立行政法人 国立精神・神経医療研究センター |
再発寛解型多発性硬化症(rrms)患者の治療予後予測方法、及び新規治療適応判断方法
|
EP2835135A3
(en)
|
2013-06-19 |
2015-06-24 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Berlin |
Means and methods for treating pseudomonas infection
|
WO2014209384A1
(en)
|
2013-06-28 |
2014-12-31 |
Amgen Inc. |
Methods for treating homozygous familial hypercholesterolema
|
WO2014207213A1
(en)
|
2013-06-28 |
2014-12-31 |
Medizinische Universität Innsbruck |
Novel inhibitors of protein kinase c epsilon signaling
|
CN105593242B
(zh)
|
2013-07-11 |
2020-11-06 |
斯克利普斯研究所 |
卷曲螺旋免疫球蛋白融合蛋白及其组合物
|
WO2015017146A2
(en)
|
2013-07-18 |
2015-02-05 |
Fabrus, Inc. |
Antibodies with ultralong complementarity determining regions
|
PT3027642T
(pt)
|
2013-07-31 |
2020-10-30 |
Amgen Inc |
Construtos do fator 15 de diferenciação de crescimento (gdf-15)
|
WO2015022326A1
(en)
|
2013-08-12 |
2015-02-19 |
Xiber Science Gmbh |
Peptides as active agents for treating primary graft dysfunction
|
TW201605896A
(zh)
|
2013-08-30 |
2016-02-16 |
安美基股份有限公司 |
Gitr抗原結合蛋白
|
CA2923145A1
(en)
|
2013-09-05 |
2015-03-12 |
Amgen Inc. |
Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
|
CA2923835C
(en)
|
2013-09-11 |
2022-11-29 |
The Administrators Of The Tulane Educational Fund |
Novel anthranilic amides and the use thereof
|
AR097648A1
(es)
|
2013-09-13 |
2016-04-06 |
Amgen Inc |
Combinación de factores epigenéticos y compuestos biespecíficos que tienen como diana cd33 y cd3 en el tratamiento de leucemia mieloide
|
WO2015038938A1
(en)
|
2013-09-13 |
2015-03-19 |
The California Institute For Biomedical Research |
Modified therapeutic agents and compositions thereof
|
PL3494985T3
(pl)
|
2013-09-16 |
2021-08-02 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
Kompozycja szczepionki zawierająca kalretikulinę
|
EP3047857A4
(en)
|
2013-09-20 |
2017-08-09 |
Chugai Seiyaku Kabushiki Kaisha |
Treatment for hemorrhagic diseases by anti-protein-c antibody
|
WO2015048331A1
(en)
|
2013-09-25 |
2015-04-02 |
Cornell University |
Compounds for inducing anti-tumor immunity and methods thereof
|
WO2015051302A1
(en)
|
2013-10-04 |
2015-04-09 |
Aptose Biosciences Inc. |
Compositions and methods for treating cancers
|
BR112016002012A2
(pt)
|
2013-10-11 |
2017-08-01 |
Hoffmann La Roche |
compostos de sulfonamida heterocíclica substituída úteis como moduladores de trpa1
|
EP3057992B1
(en)
|
2013-10-15 |
2024-04-17 |
GeneFrontier Corporation |
Human antibody against aggrecanase-type adamts species for therapeutics of aggrecanase-related diseases
|
WO2015057834A1
(en)
|
2013-10-15 |
2015-04-23 |
The California Institute For Biomedical Research |
Peptidic chimeric antigen receptor t cell switches and uses thereof
|
EP3057991B8
(en)
|
2013-10-15 |
2019-09-04 |
The Scripps Research Institute |
Chimeric antigen receptor t cell switches and uses thereof
|
WO2015057908A1
(en)
|
2013-10-18 |
2015-04-23 |
Novartis Ag |
Methods of treating diabetes and related disorders
|
ES2759252T3
(es)
|
2013-10-31 |
2020-05-08 |
Resolve Therapeutics Llc |
Fusiones y métodos terapéuticos de nucleasa-albúmina
|
AU2014364589B2
(en)
|
2013-12-18 |
2020-02-27 |
The California Institute For Biomedical Research |
Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
|
MX2016008110A
(es)
|
2013-12-20 |
2016-08-19 |
Hoffmann La Roche |
Derivados de pirazol como inhibidores de la cinasa de cremallera de leucina dual (dlk) y usos de los mismos.
|
CN103965357B
(zh)
|
2013-12-31 |
2016-08-17 |
嘉和生物药业有限公司 |
一种抗人rankl抗体
|
WO2015110930A1
(en)
|
2014-01-24 |
2015-07-30 |
Pfizer Inc. |
Modified interleukin 21 receptor proteins
|
WO2015120187A1
(en)
|
2014-02-05 |
2015-08-13 |
The University Of Chicago |
Chimeric antigen receptors recognizing cancer-spevific tn glycopeptide variants
|
US10532083B2
(en)
|
2014-02-13 |
2020-01-14 |
Technische Universität München |
Methods for inducing differentiation or conversion of white adipocytes and/or preadipocytes to brown adipocites using FGF8
|
RU2019119862A
(ru)
|
2014-02-20 |
2019-07-15 |
Аллерган, Инк. |
Антитела к компоненту комплемента c5
|
RU2673036C2
(ru)
|
2014-02-27 |
2018-11-21 |
Аллерган, Инк. |
АНТИТЕЛА К ФАКТОРУ КОМПЛЕМЕНТА Bb
|
WO2015134973A1
(en)
|
2014-03-07 |
2015-09-11 |
The Johns Hopkins University |
Inhibitors of histone lysine specific demethylase (lsd1) and histone deacetylases (hdacs)
|
CA2888068A1
(en)
|
2014-04-15 |
2015-10-15 |
The Hospital For Sick Children |
Cationic antimicrobial peptides
|
US20170073690A1
(en)
|
2014-05-15 |
2017-03-16 |
CEMM - Forschungzentrum Fuer Molekulare Medizin GMBH |
Antagonists of slc38a9 and their use in therapy
|
US20170119851A1
(en)
|
2014-05-19 |
2017-05-04 |
Novartis Ag |
Methods of treating anorexia
|
EP2947460A1
(en)
|
2014-05-22 |
2015-11-25 |
Medizinische Universität Wien |
Personalized therapy of inflammation-associated cancer using methods of assessing the susceptibility of a subject to the treatment with EGFR inhibitors/antagonists
|
WO2015184260A2
(en)
|
2014-05-30 |
2015-12-03 |
The Johns Hopkins University |
Methods for treating mendelian disorders of the epigenetic machinery
|
WO2015187779A1
(en)
|
2014-06-03 |
2015-12-10 |
Xbiotech, Inc. |
Compositions and methods for treating and preventing staphylococcus aureus infections
|
US10639360B2
(en)
|
2014-06-09 |
2020-05-05 |
Ultragenyx Pharmaceutical, Inc. |
Methods for treating hypophosphatemic disorders
|
CN107074931A
(zh)
|
2014-06-13 |
2017-08-18 |
圣塔玛丽亚生物疗法公司 |
经配制的受体多肽和相关方法
|
TW201625299A
(zh)
|
2014-06-20 |
2016-07-16 |
Chugai Pharmaceutical Co Ltd |
用於因第viii凝血因子及/或活化的第viii凝血因子的活性降低或欠缺而發病及/或進展的疾病之預防及/或治療之醫藥組成物
|
WO2016007534A1
(en)
|
2014-07-07 |
2016-01-14 |
Genentech, Inc. |
Therapeutic compounds and methods of use thereof
|
WO2016007919A2
(en)
|
2014-07-11 |
2016-01-14 |
Regents Of The University Of Minnesota |
Antibody fragments for detecting cancer and methods of use
|
AR101669A1
(es)
|
2014-07-31 |
2017-01-04 |
Amgen Res (Munich) Gmbh |
Constructos de anticuerpos para cdh19 y cd3
|
AU2015294834B2
(en)
|
2014-07-31 |
2021-04-29 |
Amgen Research (Munich) Gmbh |
Optimized cross-species specific bispecific single chain antibody constructs
|
WO2016025645A1
(en)
|
2014-08-12 |
2016-02-18 |
Massachusetts Institute Of Technology |
Synergistic tumor treatment with il-2, a therapeutic antibody, and an immune checkpoint blocker
|
DK3180018T3
(da)
|
2014-08-12 |
2019-10-28 |
Massachusetts Inst Technology |
Synergistisk tumorbehandling med IL-2 og integrinbindende Fc-fusionsprotein
|
WO2016029191A2
(en)
|
2014-08-22 |
2016-02-25 |
Auckland Uniservices Limited |
Channel modulators
|
EP3186378A1
(en)
|
2014-08-27 |
2017-07-05 |
Peptimed, Inc. |
Anti-tumor compositions and methods
|
WO2016040767A2
(en)
|
2014-09-12 |
2016-03-17 |
Amgen Inc. |
Chrdl-1 epitopes and antibodies
|
EP3000814A1
(en)
|
2014-09-26 |
2016-03-30 |
Domain Therapeutics |
Substituted pyrazoloquinazolinones and pyrroloquinazolinones as allosteric modulators of group II metabotropic glutamate receptors
|
JP6821560B2
(ja)
|
2014-10-21 |
2021-01-27 |
サイクロン ファーマシューティカルズ インターナショナル エルティーディー.Sciclone Pharmaceuticals International Ltd. |
免疫刺激剤による癌治療
|
TW202124419A
(zh)
|
2014-10-24 |
2021-07-01 |
美商必治妥美雅史谷比公司 |
經修飾之fgf-21多肽及其用途
|
WO2016069889A1
(en)
|
2014-10-31 |
2016-05-06 |
Resolve Therapeutics, Llc |
Therapeutic nuclease-transferrin fusions and methods
|
WO2016079321A1
(en)
|
2014-11-20 |
2016-05-26 |
Cemm Forschungszentrum Für Molekulare Medizin Gmbh |
Antagonists of setdb2 for use in the therapy of infectious diseases
|
EP3085709B1
(en)
|
2014-12-28 |
2019-08-21 |
Genor Biopharma Co., Ltd |
Humanized anti-human rankl antibody, pharmaceutical composition and use thereof
|
CN107683289B
(zh)
|
2015-01-26 |
2021-08-06 |
芝加哥大学 |
IL13Rα2结合剂和其在癌症治疗中的用途
|
JP6912386B2
(ja)
|
2015-01-26 |
2021-08-04 |
ザ ユニバーシティー オブ シカゴ |
癌特異的なIL13Rα2を認識するCAR T細胞
|
WO2016135138A1
(en)
|
2015-02-23 |
2016-09-01 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
Oxoquinoline derivatives as mth1 inhibitors for the therapy of cancer
|
WO2016135137A1
(en)
|
2015-02-23 |
2016-09-01 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
Substituted 4-(phenylamino)quinoline derivatives as mth1 inhibitors for the therapy of cancer
|
WO2016135140A1
(en)
|
2015-02-23 |
2016-09-01 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
4-aminoquinazoline derivatives as mth1 inhibitors for the therapy of cancer
|
JP6959869B2
(ja)
|
2015-02-23 |
2021-11-05 |
シーガル セラピューティクス エスアーエス |
非天然セマフォリン3およびそれらの医学的使用
|
WO2016135139A1
(en)
|
2015-02-23 |
2016-09-01 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
2,3-dihydrocyclopenta[b]quinoline derivatives as mth1 inhibitors for the therapy of cancer
|
RU2730590C2
(ru)
|
2015-02-27 |
2020-08-24 |
Чугаи Сейяку Кабусики Кайся |
Композиция для лечения заболеваний, связанных с ил-6
|
WO2016142310A1
(en)
|
2015-03-09 |
2016-09-15 |
F. Hoffmann-La Roche Ag |
Tricyclic dlk inhibitors and uses thereof
|
US10800828B2
(en)
|
2015-03-26 |
2020-10-13 |
The Scripps Research Institute |
Switchable non-scFv chimeric receptors, switches, and methods of use thereof to treat cancer
|
MY188430A
(en)
|
2015-04-10 |
2021-12-08 |
Amgen Inc |
Interleukin-2 muteins for the expansion of t-regulatory cells
|
US11091546B2
(en)
|
2015-04-15 |
2021-08-17 |
The Scripps Research Institute |
Optimized PNE-based chimeric receptor T cell switches and uses thereof
|
WO2016166360A1
(en)
|
2015-04-17 |
2016-10-20 |
Bayer Pharma Aktiengesellschaft |
Bispecific antibody constructs for cdh3 and cd3
|
US10864190B2
(en)
|
2015-04-22 |
2020-12-15 |
CeMM—FORSCHUNGSZENTRUM FÜR MOLEKULARE MEDIZIN GmbH |
Combination of an antiandrogen with a vitamin K antagonist or with a gamma-glutamyl carboxylase inhibitor for the therapy of androgen receptor positive cancer
|
US20180146703A1
(en)
*
|
2015-05-15 |
2018-05-31 |
The Johns Hopkins University |
Novel fluoride prenatal dietary supplement
|
EP3297989A1
(en)
|
2015-05-22 |
2018-03-28 |
Genentech, Inc. |
Substituted benzamides and methods of use thereof
|
US20160361380A1
(en)
|
2015-06-12 |
2016-12-15 |
Nymox Corporation |
Combination compositions for treating disorders requiring removal or destruction of unwanted cellular proliferations
|
EP3310376A4
(en)
|
2015-06-17 |
2019-01-23 |
The California Institute for Biomedical Research |
MODIFIED THERAPEUTIC AGENTS AND COMPOSITIONS THEREOF
|
EP3319613B1
(en)
|
2015-07-07 |
2023-02-22 |
The Research Foundation for The State University of New York |
Use of amine carboxyboranes as therapeutic delivery of carbon monoxide and as general drug delivery system in the presence of reactive oxygen species
|
EP3328375B1
(en)
|
2015-07-31 |
2022-08-31 |
The Johns Hopkins University |
Methods for cancer and immunotherapy using glutamine analogues, including don
|
TWI829617B
(zh)
|
2015-07-31 |
2024-01-21 |
德商安美基研究(慕尼黑)公司 |
Flt3及cd3抗體構築體
|
TWI717375B
(zh)
|
2015-07-31 |
2021-02-01 |
德商安美基研究(慕尼黑)公司 |
Cd70及cd3抗體構築體
|
US10842763B2
(en)
|
2015-07-31 |
2020-11-24 |
The Johns Hopkins University |
Methods for cancer and immunotherapy using prodrugs of glutamine analogs
|
TWI796283B
(zh)
|
2015-07-31 |
2023-03-21 |
德商安美基研究(慕尼黑)公司 |
Msln及cd3抗體構築體
|
CN108135872A
(zh)
|
2015-07-31 |
2018-06-08 |
约翰霍普金斯大学 |
用于治疗认知缺陷的谷氨酰胺拮抗剂
|
CA2994258A1
(en)
|
2015-07-31 |
2017-02-09 |
The Johns Hopkins University |
Prodrugs of glutamine analogs
|
TWI744242B
(zh)
|
2015-07-31 |
2021-11-01 |
德商安美基研究(慕尼黑)公司 |
Egfrviii及cd3抗體構築體
|
TWI793062B
(zh)
|
2015-07-31 |
2023-02-21 |
德商安美基研究(慕尼黑)公司 |
Dll3及cd3抗體構築體
|
JO3620B1
(ar)
|
2015-08-05 |
2020-08-27 |
Amgen Res Munich Gmbh |
مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم
|
WO2017035271A1
(en)
|
2015-08-27 |
2017-03-02 |
Genentech, Inc. |
Therapeutic compounds and methods of use thereof
|
CN108348581B
(zh)
|
2015-09-04 |
2022-07-01 |
斯克利普斯研究所 |
胰岛素免疫球蛋白融合蛋白
|
WO2017059371A1
(en)
|
2015-10-01 |
2017-04-06 |
Amgen Inc. |
Treatment of bile acid disorders
|
US20180320136A1
(en)
|
2015-11-03 |
2018-11-08 |
GlycoMimitics, Inc. |
Methods and compositions for the production of monoclonal antibodies, hematopoietic stem cells, and methods of using the same
|
CN108834415B
(zh)
|
2015-11-13 |
2021-12-24 |
多曼治疗学公司 |
作为ii组代谢型谷氨酸受体的别构调节剂的取代的三环1,4-苯并二氮杂䓬酮衍生物
|
WO2017086367A1
(ja)
|
2015-11-18 |
2017-05-26 |
中外製薬株式会社 |
免疫抑制機能を有する細胞に対するt細胞リダイレクト抗原結合分子を用いた併用療法
|
EP3378488A4
(en)
|
2015-11-18 |
2019-10-30 |
Chugai Seiyaku Kabushiki Kaisha |
METHOD FOR ENHANCING THE HUMORAL IMMUNE RESPONSE
|
CN108495851A
(zh)
|
2015-11-25 |
2018-09-04 |
基因泰克公司 |
取代的苯甲酰胺及其使用方法
|
US20170157215A1
(en)
|
2015-12-04 |
2017-06-08 |
Jomoco, Corp. |
Compositions and methods to mitigate or prevent an immune response to an immunogenic therapeutic molecule in non-human primates
|
US10723748B2
(en)
|
2015-12-09 |
2020-07-28 |
Medizinische Universität Wien |
Monomaleimide-functionalized platinum compounds for cancer therapy
|
ES2903257T3
(es)
|
2015-12-09 |
2022-03-31 |
Scripps Research Inst |
Proteínas de fusión de inmunoglobulina de relaxina y métodos de uso
|
IL296682A
(en)
|
2015-12-23 |
2022-11-01 |
Amgen Inc |
A method for treating or improving metabolic disorders using gastric inhibitory peptide receptor binding proteins in combination with glucagon-like peptide 1 agonists
|
EP3395835B1
(en)
|
2015-12-25 |
2021-02-03 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody having enhanced activity, and method for modifying same
|
EP3402788A1
(en)
|
2016-01-15 |
2018-11-21 |
Universität Hamburg |
Flavonoide-type compounds bearing an o-rhamnosyl residue
|
TWI797073B
(zh)
|
2016-01-25 |
2023-04-01 |
德商安美基研究(慕尼黑)公司 |
包含雙特異性抗體建構物之醫藥組合物
|
IL260958B1
(en)
|
2016-02-03 |
2024-07-01 |
Amgen Res Munich Gmbh |
Constructs of bispecific antibodies to BCMA and CD3 that bind to T cells, preparations containing the same and uses thereof
|
LT3411404T
(lt)
|
2016-02-03 |
2022-12-27 |
Amgen Research (Munich) Gmbh |
Psma ir cd3 bispecifiniai, t ląsteles aktyvuojantys antikūno konstruktai
|
EA039859B1
(ru)
|
2016-02-03 |
2022-03-21 |
Эмджен Рисерч (Мюник) Гмбх |
Биспецифические конструкты антител, связывающие egfrviii и cd3
|
US10098909B2
(en)
|
2016-02-05 |
2018-10-16 |
University Of South Florida |
Ionic cocrystal of lithium, lispro, for the treatment of fragile X syndrome
|
EP3414573B1
(en)
|
2016-02-10 |
2023-11-08 |
Rutgers, the State University of New Jersey |
Novel anti-lam antibodies
|
AU2017220611A1
(en)
|
2016-02-15 |
2018-08-30 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
TAF1 inhibitors for the therapy of cancer
|
EP3216458A1
(en)
|
2016-03-07 |
2017-09-13 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Modified vascular endothelial growth factor a (vegf-a) and its medical use
|
KR101834708B1
(ko)
|
2016-03-14 |
2018-03-06 |
추가이 세이야쿠 가부시키가이샤 |
암의 치료에 이용하기 위한 세포상해 유도 치료제
|
WO2017172802A1
(en)
|
2016-03-30 |
2017-10-05 |
Genentech, Inc. |
Substituted benzamides and methods of use thereof
|
WO2017178820A1
(en)
|
2016-04-15 |
2017-10-19 |
Oxford University Innovation Limited |
Adenosine receptor modulators for the treatment of circadian rhythm disorders
|
CN109071623B
(zh)
|
2016-05-04 |
2022-05-27 |
美国安进公司 |
用于扩增t调节性细胞的白细胞介素-2突变蛋白
|
US10183058B2
(en)
|
2016-06-17 |
2019-01-22 |
Nymox Corporation |
Method of preventing or reducing the progression of prostate cancer
|
DK3478830T3
(da)
|
2016-07-01 |
2024-05-21 |
Resolve Therapeutics Llc |
Optimerede binucleasefusioner og metoder
|
US10300145B2
(en)
|
2016-07-15 |
2019-05-28 |
Massachusetts Institute Of Technology |
Synthetic nanoparticles for delivery of immunomodulatory compounds
|
EP3487853B1
(en)
|
2016-07-20 |
2022-06-08 |
F. Hoffmann-La Roche AG |
Bicyclic proline compounds
|
WO2018015411A1
(en)
|
2016-07-20 |
2018-01-25 |
F. Hoffmann-La Roche Ag |
Sulfonylcycloalkyl carboxamide compounds as trpa1 modulators
|
US10172910B2
(en)
|
2016-07-28 |
2019-01-08 |
Nymox Corporation |
Method of preventing or reducing the incidence of acute urinary retention
|
US20200030295A1
(en)
|
2016-08-02 |
2020-01-30 |
Friedrich-Alexander-Universität Erlangen-Nürnberg |
Heterocyclic diamidines
|
AU2017310412A1
(en)
|
2016-08-08 |
2019-02-21 |
Amgen Inc. |
Method of improving connective tissue attachment using anti-sclerostin antibodies
|
EP3497093B1
(en)
|
2016-08-12 |
2021-09-15 |
F. Hoffmann-La Roche AG |
Sulfonyl pyridyl trp inhibitors
|
US10981976B2
(en)
|
2016-08-31 |
2021-04-20 |
University Of Rochester |
Human monoclonal antibodies to human endogenous retrovirus K envelope (HERV-K) and use thereof
|
JP7125932B2
(ja)
|
2016-09-06 |
2022-08-25 |
中外製薬株式会社 |
凝固第ix因子および/または活性化凝固第ix因子ならびに凝固第x因子および/または活性化凝固第x因子を認識する二重特異性抗体の使用法
|
US10532081B2
(en)
|
2016-09-07 |
2020-01-14 |
Nymox Corporation |
Method of ameliorating or preventing the worsening or the progression of symptoms of BPH
|
WO2018053222A1
(en)
|
2016-09-16 |
2018-03-22 |
Research Traingle Institute |
Tetrahydroisoquinoline kappa opioid antagonists
|
EP3526219B1
(en)
|
2016-10-17 |
2021-12-15 |
F. Hoffmann-La Roche AG |
Bicyclic pyridone lactams and methods of use thereof
|
KR20230172612A
(ko)
|
2016-10-19 |
2023-12-22 |
더 스크립스 리서치 인스티튜트 |
인간화된 표적화 모이어티 및/또는 최적화된 키메라 항원 수용체-상호작용 도메인을 갖는 키메라 항원 수용체 효과기 세포 스위치 및 이의 용도
|
EP3538100A2
(en)
|
2016-11-14 |
2019-09-18 |
CeMM - Forschungszentrum für Molekulare Medizin GmbH |
Combination of a brd4 inhibitor and an antifolate for the therapy of cancer
|
EP3544979B1
(en)
|
2016-11-28 |
2021-08-04 |
F. Hoffmann-La Roche AG |
Oxadiazolones as transient receptor potential channel inhibitors
|
MA46937A
(fr)
|
2016-11-30 |
2019-10-09 |
Oncotyrol Center For Personalized Cancer Medicine Gmbh |
3-amino-1,5-dihydro-pyrazolo[3,4-d]pyrimidin-4-ones en tant qu'inhibiteurs de kinases dépendantes des cyclines
|
EP3548484A1
(en)
|
2016-12-02 |
2019-10-09 |
H. Hoffnabb-La Roche Ag |
Bicyclic amide compounds and methods of use thereof
|
US11072607B2
(en)
|
2016-12-16 |
2021-07-27 |
Genentech, Inc. |
Inhibitors of RIP1 kinase and methods of use thereof
|
WO2018128454A1
(ko)
|
2017-01-06 |
2018-07-12 |
에이비엘바이오 주식회사 |
항 α-SYN 항체 및 그 용도
|
AU2018207303A1
(en)
|
2017-01-10 |
2019-07-25 |
xCella Biosciences, Inc. |
Combination tumor treatment with an integrin-binding-Fc fusion protein and immune modulator
|
US10350266B2
(en)
|
2017-01-10 |
2019-07-16 |
Nodus Therapeutics, Inc. |
Method of treating cancer with a multiple integrin binding Fc fusion protein
|
WO2018130554A1
(en)
|
2017-01-11 |
2018-07-19 |
Paracelsus Medizinische Privatuniversität Salzburg - Privatstiftung |
Mesenchymal stem cell-derived extracellular vesicles and their medical use
|
JOP20190177A1
(ar)
|
2017-01-17 |
2019-07-16 |
Amgen Inc |
طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr)
|
JOP20190189A1
(ar)
|
2017-02-02 |
2019-08-01 |
Amgen Res Munich Gmbh |
تركيبة صيدلانية ذات درجة حموضة منخفضة تتضمن بنيات جسم مضاد يستهدف الخلية t
|
WO2018148419A1
(en)
|
2017-02-08 |
2018-08-16 |
Bristol-Myers Squibb Company |
Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
|
US10335453B2
(en)
|
2017-03-01 |
2019-07-02 |
Nymox Corporation |
Compositions and methods for improving sexual function
|
WO2018160791A1
(en)
|
2017-03-03 |
2018-09-07 |
Massachusetts Institute Of Technology |
Antimicrobial constructs and uses thereof
|
CN114874209A
(zh)
|
2017-03-07 |
2022-08-09 |
豪夫迈·罗氏有限公司 |
噁二唑瞬时受体电位通道抑制剂
|
JP2020511511A
(ja)
|
2017-03-24 |
2020-04-16 |
ジェネンテック, インコーポレイテッド |
ナトリウムチャネル阻害剤としての4−ピペリジン−n−(ピリミジン−4−イル)クロマン−7−スルホンアミド誘導体
|
US11851486B2
(en)
|
2017-05-02 |
2023-12-26 |
National Center Of Neurology And Psychiatry |
Method for predicting and evaluating therapeutic effect in diseases related to IL-6 and neutrophils
|
WO2018204907A1
(en)
|
2017-05-05 |
2018-11-08 |
Amgen Inc. |
Pharmaceutical composition comprising bispecific antibody constructs for improved storage and administration
|
CA3062749A1
(en)
|
2017-05-12 |
2018-11-15 |
Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. |
Compounds for use in the treatment or prevention of melanoma
|
WO2018206820A1
(en)
|
2017-05-12 |
2018-11-15 |
Mavalon Therapeutics Limited |
Substituted heterocyclic compounds as allosteric modulators of group ii metabotropic glutamate receptors
|
JOP20190259A1
(ar)
|
2017-05-31 |
2019-10-31 |
Amgen Inc |
بروتينات ربط مولد ضد مضادة لـ jagged1
|
WO2018236904A1
(en)
|
2017-06-19 |
2018-12-27 |
Surface Oncology, Inc. |
COMBINATION OF ANTI-CD47 ANTIBODIES AND CELL DEATH INDUCING AGENTS, AND USES THEREOF
|
CN110831969B
(zh)
|
2017-06-20 |
2024-06-21 |
安进公司 |
使用抑胃肽受体(gipr)结合蛋白与glp-1激动剂的组合治疗或改善代谢障碍的方法
|
MA49565A
(fr)
|
2017-07-11 |
2020-05-20 |
Compass Therapeutics Llc |
Anticorps agonistes qui lient cd137 humain et leurs utilisations
|
AU2018300043B2
(en)
|
2017-07-14 |
2021-04-01 |
F. Hoffmann-La Roche Ag |
Bicyclic ketone compounds and methods of use thereof
|
US11344603B2
(en)
|
2017-07-19 |
2022-05-31 |
Auckland Uniservices Limited |
Cytokine modulation
|
US11077199B2
(en)
|
2017-08-09 |
2021-08-03 |
Massachusetts Institute Of Technology |
Albumin binding peptide conjugates and methods thereof
|
EP3672986A1
(en)
|
2017-08-22 |
2020-07-01 |
Sanabio, LLC |
Soluble interferon receptors and uses thereof
|
WO2019060425A1
(en)
|
2017-09-19 |
2019-03-28 |
Massachusetts Institute Of Technology |
COMPOSITIONS FOR CHIMERIC ANTIGENIC RECEPTOR T CELL THERAPY AND USES THEREOF
|
US20200317795A1
(en)
|
2017-10-04 |
2020-10-08 |
Amgen Inc. |
Transthyretin immunoglobulin fusions
|
MA50356A
(fr)
|
2017-10-11 |
2021-04-21 |
Hoffmann La Roche |
Composés bicycliques destinés à être utilisés en tant qu'inhibiteurs de la kinase rip1
|
KR20200074160A
(ko)
|
2017-10-20 |
2020-06-24 |
가꼬우호우징 효고 이카다이가쿠 |
항il-6 수용체 항체를 함유하는 수술 후의 유착을 억제하기 위한 의약 조성물
|
WO2019089365A1
(en)
|
2017-10-30 |
2019-05-09 |
Enterin Laboratories, Inc. |
New squalamine solid forms and methods of making the same
|
RU2020115915A
(ru)
|
2017-10-31 |
2021-12-01 |
Ф. Хоффманн-Ля Рош Аг |
Бициклические сульфоны и сульфоксиды и способы их применения
|
US11718679B2
(en)
|
2017-10-31 |
2023-08-08 |
Compass Therapeutics Llc |
CD137 antibodies and PD-1 antagonists and uses thereof
|
US11851497B2
(en)
|
2017-11-20 |
2023-12-26 |
Compass Therapeutics Llc |
CD137 antibodies and tumor antigen-targeting antibodies and uses thereof
|
US20210179591A1
(en)
|
2017-12-05 |
2021-06-17 |
Eth Zurich |
New compounds for use as a therapeutically active substance and in particular for use in the treatment of tumors
|
JP7344206B2
(ja)
|
2017-12-11 |
2023-09-13 |
アムジェン インコーポレイテッド |
二重特異性抗体製品のための連続製造プロセス
|
JP2021506851A
(ja)
|
2017-12-19 |
2021-02-22 |
マサチューセッツ インスティテュート オブ テクノロジー |
抗原−アジュバントカップリング試薬および使用の方法
|
WO2019131988A1
(en)
|
2017-12-28 |
2019-07-04 |
Chugai Seiyaku Kabushiki Kaisha |
Cytotoxicity-inducing therapeutic agent
|
UY38041A
(es)
|
2017-12-29 |
2019-06-28 |
Amgen Inc |
Construcción de anticuerpo biespecífico dirigida a muc17 y cd3
|
TWI822728B
(zh)
|
2018-01-31 |
2023-11-21 |
加藤元一 |
含有il-6抑制劑的哮喘治療劑
|
EP3749353A1
(en)
|
2018-02-09 |
2020-12-16 |
Nestlé Skin Health SA |
Nemolizumab in the treatment of atopic dermatitis with moderate to severe excoriation
|
AR114585A1
(es)
|
2018-02-20 |
2020-09-23 |
Hoffmann La Roche |
Proceso para preparar compuestos antagonistas de canales potenciales transitorios del receptor de 1-arilsulfonil-pirrolidin-2-carboxamida y formas cristalinas de los mismos
|
WO2019165290A1
(en)
|
2018-02-26 |
2019-08-29 |
Genentech, Inc. |
Pyridine-sulfonamide compounds and their use against pain and related conditions
|
BR112020018480B1
(pt)
|
2018-03-14 |
2022-09-27 |
Surface Oncology, Inc |
Usos de anticorpos que se ligam a cd39 no tratamento de câncer
|
US10710994B2
(en)
|
2018-03-19 |
2020-07-14 |
Genentech, Inc. |
Oxadiazole transient receptor potential channel inhibitors
|
CA3093740A1
(en)
|
2018-03-22 |
2019-09-26 |
Surface Oncology, Inc. |
Anti-il-27 antibodies and uses thereof
|
EP3774801A1
(en)
|
2018-03-30 |
2021-02-17 |
F. Hoffmann-La Roche AG |
Fused ring hydro-pyrido compounds as sodium channel inhibitors
|
WO2019191534A1
(en)
|
2018-03-30 |
2019-10-03 |
Amgen Inc. |
C-terminal antibody variants
|
WO2019193159A1
(en)
|
2018-04-06 |
2019-10-10 |
Universität Wien |
Bumetanide derivatives for the therapy of hyperhidrosis
|
WO2019193161A1
(en)
|
2018-04-06 |
2019-10-10 |
Universität Wien |
Bumetanide derivatives for the therapy of stroke and other neurological diseases/disorders involving nkccs
|
CR20200510A
(es)
|
2018-04-09 |
2020-11-26 |
Amgen Inc |
Protreínas de fusión del factor de diferenciación de crecimiento 15
|
WO2019200357A1
(en)
|
2018-04-12 |
2019-10-17 |
Surface Oncology, Inc. |
Biomarker for cd47 targeting therapeutics and uses therefor
|
CA3093715A1
(en)
|
2018-04-19 |
2019-10-24 |
Checkmate Pharmaceuticals, Inc. |
Synthetic rig-i-like receptor agonists
|
EP3781571B1
(en)
|
2018-04-20 |
2024-01-17 |
F. Hoffmann-La Roche AG |
N-[4-oxo-2,3-dihydro-pyrido[3,2-b][1,4]oxazepin-3-yl]-5,6-dihydro-4h-pyrrolo[1,2-b]pyrazole-2-carboxamide derivatives and related compounds as rip1 kinase inhibitors for treating e.g. irritable bowel syndrome (ibs)
|
WO2019207051A1
(en)
|
2018-04-25 |
2019-10-31 |
Università Degli Studi Di Torino |
Medical use of combinations of non-natural semaphorins 3 and antimetabolites
|
EP3797120A1
(en)
|
2018-05-21 |
2021-03-31 |
Compass Therapeutics LLC |
Compositions and methods for enhancing the killing of target cells by nk cells
|
WO2019226658A1
(en)
|
2018-05-21 |
2019-11-28 |
Compass Therapeutics Llc |
Multispecific antigen-binding compositions and methods of use
|
TW202003490A
(zh)
|
2018-05-22 |
2020-01-16 |
瑞士商赫孚孟拉羅股份公司 |
治療性化合物及其使用方法
|
WO2019225787A1
(ko)
|
2018-05-24 |
2019-11-28 |
에이비엘바이오 주식회사 |
항-b7-h3 항체 및 그 용도
|
WO2020011938A1
(en)
|
2018-07-11 |
2020-01-16 |
Medizinische Universität Wien |
Glucocorticoids for the topical treatment of autoimmune gastritis
|
US20220275043A1
(en)
|
2018-07-17 |
2022-09-01 |
Massachusetts Institute Of Technology |
Soluble multimeric immunoglobulin-scaffold based fusion proteins and uses thereof
|
US20210309746A1
(en)
|
2018-08-09 |
2021-10-07 |
Compass Therapeutics Llc |
Antibodies that bind cd277 and uses thereof
|
WO2020033925A2
(en)
|
2018-08-09 |
2020-02-13 |
Compass Therapeutics Llc |
Antibodies that bind cd277 and uses thereof
|
US20210388089A1
(en)
|
2018-08-09 |
2021-12-16 |
Compass Therapeutics Llc |
Antigen binding agents that bind cd277 and uses thereof
|
AU2019327456A1
(en)
|
2018-08-28 |
2021-04-15 |
Ambrx, Inc. |
anti-CD3 antibody folate bioconjugates and their uses
|
TW202024023A
(zh)
|
2018-09-03 |
2020-07-01 |
瑞士商赫孚孟拉羅股份公司 |
治療性化合物及其使用方法
|
AU2019337610A1
(en)
|
2018-09-11 |
2021-05-06 |
Ambrx, Inc. |
Interleukin-2 polypeptide conjugates and their uses
|
WO2020053808A1
(en)
|
2018-09-12 |
2020-03-19 |
Georg Dewald |
Method of diagnosing vasoregulatory disorders
|
CN112771071A
(zh)
|
2018-09-28 |
2021-05-07 |
麻省理工学院 |
胶原蛋白定位的免疫调节分子及其方法
|
AU2019356564A1
(en)
|
2018-10-11 |
2021-04-29 |
Amgen Inc. |
Downstream processing of bispecific antibody constructs
|
AU2019361206A1
(en)
|
2018-10-19 |
2021-06-03 |
Ambrx, Inc. |
Interleukin-10 polypeptide conjugates, dimers thereof, and their uses
|
US20230067929A1
(en)
|
2018-12-17 |
2023-03-02 |
Tolremo Therapeutics Ag |
Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment, amelioration or prevention of cancer
|
BR112021013096A2
(pt)
|
2019-01-04 |
2022-04-19 |
Resolve Therapeutics, Llc |
Tratamento de doença de sjögren com proteínas de fusão de nuclease
|
AR119673A1
(es)
|
2019-01-11 |
2022-01-05 |
Hoffmann La Roche |
Compuestos bicíclicos de cetona y métodos para utilizarlos
|
US11680105B2
(en)
|
2019-01-17 |
2023-06-20 |
Regents Of The University Of Minnesota |
Antibody fragments for detecting cancer and methods of use
|
WO2020154032A1
(en)
|
2019-01-23 |
2020-07-30 |
Massachusetts Institute Of Technology |
Combination immunotherapy dosing regimen for immune checkpoint blockade
|
US11236157B2
(en)
|
2019-01-28 |
2022-02-01 |
Galderma Holding SA |
Treatment of skin lesions and pruritus in prurigo nodularis patients
|
MX2021009644A
(es)
|
2019-02-12 |
2021-09-08 |
Ambrx Inc |
Composiciones que contienen, metodos y usos de conjugados de anticuerpo-agonista de tlr.
|
EP3941511A2
(en)
|
2019-03-20 |
2022-01-26 |
Massachusetts Institute of Technology |
Uses of amphiphiles in immune cell therapy and compositions therefor
|
WO2020202839A1
(ja)
|
2019-03-29 |
2020-10-08 |
中外製薬株式会社 |
抗il-6受容体抗体を含有するbbb機能低下の抑制剤
|
WO2020213665A1
(ja)
|
2019-04-17 |
2020-10-22 |
国立大学法人広島大学 |
Il-6阻害剤及びccr2阻害剤を組み合わせて投与することを特徴とする泌尿器がんの治療剤
|
JPWO2020241816A1
(xx)
|
2019-05-31 |
2020-12-03 |
|
|
MX2021014433A
(es)
|
2019-06-05 |
2022-03-11 |
Chugai Pharmaceutical Co Ltd |
Molecula de union a sitio de escision de anticuerpo.
|
TW202112395A
(zh)
|
2019-06-10 |
2021-04-01 |
日商中外製藥股份有限公司 |
用於與細胞激素抑制劑組合使用之抗t細胞抗原結合分子
|
US20220259547A1
(en)
|
2019-06-13 |
2022-08-18 |
Amgeng Inc. |
Automated biomass-based perfusion control in the manufacturing of biologics
|
US11642409B2
(en)
|
2019-06-26 |
2023-05-09 |
Massachusetts Insttute of Technology |
Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
|
WO2021007150A1
(en)
|
2019-07-08 |
2021-01-14 |
Amgen Inc. |
Multispecific transthyretin immunoglobulin fusions
|
CN113950485A
(zh)
|
2019-07-10 |
2022-01-18 |
中外制药株式会社 |
密蛋白-6结合分子及其用途
|
EP4004041A1
(en)
|
2019-07-26 |
2022-06-01 |
Amgen Inc. |
Anti-il13 antigen binding proteins
|
JP2022544549A
(ja)
|
2019-08-12 |
2022-10-19 |
ピュリノミア バイオテック, インコーポレイテッド |
Cd39発現細胞のadcc標的化を介してt細胞媒介性免疫応答を促進及び増強するための方法及び組成物
|
EP4013776A1
(en)
|
2019-08-13 |
2022-06-22 |
Amgen Inc. |
Interleukin-2 muteins for the expansion of t-regulatory cells
|
CA3145940A1
(en)
|
2019-09-16 |
2021-03-25 |
Scott Chappel |
Anti-cd39 antibody compositions and methods
|
CN115087671A
(zh)
|
2019-09-25 |
2022-09-20 |
表面肿瘤学公司 |
抗il-27抗体及其用途
|
WO2021064142A1
(en)
|
2019-10-02 |
2021-04-08 |
Tolremo Therapeutics Ag |
Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment or amelioration of cancer
|
WO2021064141A1
(en)
|
2019-10-02 |
2021-04-08 |
Tolremo Therapeutics Ag |
Inhibitors of dual specificity tyrosine phosphorylation regulated kinase 1b
|
TWI745114B
(zh)
|
2019-10-11 |
2021-11-01 |
日商中外製藥股份有限公司 |
用於後天性血友病a之預防及/或治療之醫藥組成物、及包含該醫藥組成物之製品
|
AU2020366135A1
(en)
|
2019-10-16 |
2022-06-02 |
Proxygen Gmbh |
Oxazole and thioazole-type cullin ring ubiquitin ligase compounds and uses thereof
|
WO2021074418A1
(en)
|
2019-10-16 |
2021-04-22 |
Cemm - Forschungszentrum Für Molekulare Medizin Gmbh |
Carbazole-type cullin ring ubiquitin ligase compounds and uses thereof
|
US20220378817A1
(en)
|
2019-10-23 |
2022-12-01 |
Checkmate Pharmaceuticals, Inc. |
Synthetic rig-i-like receptor agonists
|
WO2021080682A1
(en)
|
2019-10-24 |
2021-04-29 |
Massachusetts Institute Of Technology |
Monoclonal antibodies that bind human cd161 and uses thereof
|
US20220380487A1
(en)
|
2019-10-24 |
2022-12-01 |
Minotaur Therapeutics, Inc. |
Chimeric cytokine modified antibodies and methods of use thereof
|
KR20220101138A
(ko)
|
2019-11-13 |
2022-07-19 |
제넨테크, 인크. |
치료적 화합물 및 사용 방법
|
AU2020381536A1
(en)
|
2019-11-13 |
2022-04-21 |
Amgen Inc. |
Method for reduced aggregate formation in downstream processing of bispecific antigen-binding molecules
|
MX2022005914A
(es)
|
2019-11-19 |
2022-08-04 |
Modag Gmbh |
Compuestos novedosos para el diagnostico, tratamiento y prevencion de enfermedades asociadas con la agregacion de alfa-sinucleina.
|
AU2020407208A1
(en)
|
2019-12-17 |
2022-06-02 |
Amgen Inc. |
Dual interleukin-2 /tnf receptor agonist for use in therapy
|
MX2022008341A
(es)
|
2020-01-06 |
2022-08-10 |
Vaccinex Inc |
Anticuerpos anti-ccr8 y usos de estos.
|
WO2021173889A1
(en)
|
2020-02-26 |
2021-09-02 |
Ambrx, Inc. |
Uses of anti-cd3 antibody folate bioconjugates
|
JP2023517595A
(ja)
|
2020-03-11 |
2023-04-26 |
アンブルックス,インコーポレイテッド |
インターロイキン-2ポリペプチド結合物およびその使用方法
|
CN115427454A
(zh)
|
2020-03-19 |
2022-12-02 |
安进公司 |
针对粘蛋白17的抗体及其用途
|
JP2023106635A
(ja)
|
2020-04-17 |
2023-08-02 |
中外製薬株式会社 |
二重特異性抗原結合分子ならびに、それに関連する組成物、組成物の製造のための使用、キット、および方法
|
WO2021221783A1
(en)
|
2020-05-01 |
2021-11-04 |
Massachusetts Institute Of Technology |
Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
|
US20210338833A1
(en)
|
2020-05-01 |
2021-11-04 |
Massachusetts Institute Of Technology |
Chimeric antigen receptor-targeting ligands and uses thereof
|
EP4161520A1
(en)
|
2020-06-05 |
2023-04-12 |
The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone |
Acvr1 (alk2) receptor inhibition to treat neurological diseases
|
GB202101299D0
(en)
|
2020-06-09 |
2021-03-17 |
Avacta Life Sciences Ltd |
Diagnostic polypetides and methods
|
CR20230014A
(es)
|
2020-06-19 |
2023-02-17 |
Chugai Pharmaceutical Co Ltd |
Molécula de unión al antígeno anti-células t para usarse en combinación con un inhibidor de angiogénesis
|
US20230226057A1
(en)
|
2020-06-25 |
2023-07-20 |
Tolremo Therapeutics Ag |
Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment, amelioration or prevention of fibrotic disease
|
US20230355722A1
(en)
|
2020-06-29 |
2023-11-09 |
Resolve Therapeutics, Llc |
Treatment of sjogren’s syndrome with nuclease fusion proteins
|
EP3939578A1
(en)
|
2020-07-13 |
2022-01-19 |
Novaremed Ltd. |
Compounds for treatment or prevention of an infection resulting from a coronavirus and/or a coronavirus-induced disease
|
US11787775B2
(en)
|
2020-07-24 |
2023-10-17 |
Genentech, Inc. |
Therapeutic compounds and methods of use
|
WO2022023292A2
(en)
|
2020-07-31 |
2022-02-03 |
Friedrich-Alexander-Universität Erlangen-Nürnberg |
Corona virus spike protein-targeting antibodies and use thereof
|
IL300225A
(en)
|
2020-07-31 |
2023-03-01 |
Chugai Pharmaceutical Co Ltd |
A pharmaceutical composition including chimeric receptor expressing cells
|
AU2021327396A1
(en)
|
2020-08-20 |
2023-03-23 |
Ambrx, Inc. |
Antibody-TLR agonist conjugates, methods and uses thereof
|
EP3964497A1
(en)
|
2020-09-04 |
2022-03-09 |
Friedrich-Alexander-Universität Erlangen-Nürnberg |
Substituted vicinal diamine compounds and their use in the treatment, amelioration or prevention of pain
|
CN116744933A
(zh)
|
2020-10-02 |
2023-09-12 |
基因泰克公司 |
用于制备双杂芳基化合物及其晶型的方法
|
WO2022087274A1
(en)
|
2020-10-21 |
2022-04-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Antibodies that neutralize type-i interferon (ifn) activity
|
AU2021374839A1
(en)
|
2020-11-06 |
2023-06-08 |
Amgen Inc. |
Multitargeting bispecific antigen-binding molecules of increased selectivity
|
AU2022224636A1
(en)
|
2021-02-19 |
2023-09-07 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Single domain antibodies that neutralize sars-cov-2
|
KR20230156368A
(ko)
|
2021-03-12 |
2023-11-14 |
추가이 세이야쿠 가부시키가이샤 |
중증 근무력증의 치료 또는 예방용의 의약 조성물
|
IL307282A
(en)
|
2021-04-03 |
2023-11-01 |
Ambrx Inc |
Antidote conjugates against HER2 and their applications
|
TW202304882A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商妥瑞莫醫療公司 |
雜環衍生物、醫藥組成物及彼等於治療或改善癌症之用途
|
EP4329887A1
(en)
|
2021-04-28 |
2024-03-06 |
Minotaur Therapeutics, Inc. |
Humanized chimeric bovine antibodies and methods of use
|
AU2022269312A1
(en)
|
2021-05-06 |
2023-10-19 |
Amgen Research (Munich) Gmbh |
Cd20 and cd22 targeting antigen-binding molecules for use in proliferative diseases
|
IL308198A
(en)
|
2021-05-07 |
2024-01-01 |
Surface Oncology Llc |
Anti-IL-27 antibodies and uses thereof
|
KR20240035394A
(ko)
|
2021-05-14 |
2024-03-15 |
클라리스 바이오쎄라퓨틱스, 인코포레이티드 |
안질환 치료를 위한 성장 인자 조성물
|
WO2023028077A1
(en)
|
2021-08-24 |
2023-03-02 |
Genentech, Inc. |
Sodium channel inhibitors and methods of designing same
|
WO2023028056A1
(en)
|
2021-08-24 |
2023-03-02 |
Genentech, Inc. |
3-amino piperidyl sodium channel inhibitors
|
EP4395657A1
(en)
|
2021-08-30 |
2024-07-10 |
Galderma Holding SA |
Treatments for atopic dermatitis
|
WO2023031881A1
(en)
|
2021-09-03 |
2023-03-09 |
University Of Bern |
Compositions and methods for treating long qt syndrome
|
WO2023053282A1
(ja)
|
2021-09-29 |
2023-04-06 |
中外製薬株式会社 |
がんの治療に用いるための細胞傷害誘導治療剤
|
AR127568A1
(es)
|
2021-11-03 |
2024-02-07 |
Affimed Gmbh |
Ligandos biespecíficos de cd16a
|
WO2023079493A1
(en)
|
2021-11-03 |
2023-05-11 |
Affimed Gmbh |
Bispecific cd16a binders
|
TW202332429A
(zh)
|
2021-11-24 |
2023-08-16 |
美商建南德克公司 |
治療性化合物及其使用方法
|
WO2023203378A1
(en)
|
2022-04-19 |
2023-10-26 |
Garth Cooper |
Treatment of brain copper disorders
|
WO2023203172A1
(en)
|
2022-04-20 |
2023-10-26 |
Proxygen Gmbh |
Heterocyclic cullin ring ubiquitin ligase compounds and uses thereof
|
TW202346368A
(zh)
|
2022-05-12 |
2023-12-01 |
德商安美基研究(慕尼黑)公司 |
具有增加的選擇性的多鏈多靶向性雙特異性抗原結合分子
|
WO2023230128A1
(en)
|
2022-05-25 |
2023-11-30 |
Surface Oncology, Inc. |
Use of anti-il-27 antibodies
|
US20240025987A1
(en)
|
2022-05-25 |
2024-01-25 |
Surface Oncology, Inc. |
Use of anti-il-27 antibodies
|
WO2024050526A1
(en)
|
2022-09-02 |
2024-03-07 |
Biomarin Pharmaceutical Inc. |
Compositions and methods for treating long qt syndrome
|
US20240141050A1
(en)
|
2022-09-02 |
2024-05-02 |
Galderma Holding S.A. |
Treatments for prurigo nodularis
|
WO2024059675A2
(en)
|
2022-09-14 |
2024-03-21 |
Amgen Inc. |
Bispecific molecule stabilizing composition
|
WO2024076995A1
(en)
|
2022-10-03 |
2024-04-11 |
Insigna Inc. |
Compositions for non-surgical prevention of boar taint and aggressive behavior
|
WO2024121796A1
(en)
|
2022-12-07 |
2024-06-13 |
Fondazione Matilde Tettamanti E Menotti De Marchi Onlus |
Methods for generating genetically modified cytokine induced killer (cik) cells
|